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ABSTRACT

ACUTE PHARMACOLOGICAL TREATMENT GIVEN TO OLDER ADULTS WITH
ACUTE MYOCARDIAL INFARCTION: A NATIONWIDE EMERGENCY DEPARTMENT
STUDY, 1992–2010
Maryam S. Alowayesh, MSc
Virginia Commonwealth University, 2013
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Spencer E. Harpe, PharmD, MPH, PhD
Associate Professor
Department of Pharmacotherapy and Outcomes Science
OBJECTIVE: To determine the pattern and predictors of use of antiplatelet agents and betablockers given in the emergency department (ED) to older adults with acute myocardial
infarction (AMI) and its effects on in-hospital mortality and length of hospital stay (LOS) and to
determine the effect of computerized ED guideline reminders on their utilization.
METHODS: A cross-sectional study using the National Hospital Ambulatory Medical Care
Survey (NHAMCS) ED data for years 1992 to 2010 was conducted. Patients were included if
they had an admission diagnosis of AMI (ICD-9-CM code 410.xx) and were ≥55 years. Survey
logistic regression was used to examine whether there was a trend in the use of antiplatelet
agents and beta-blockers across the years and to explore the association between various
predictor variables and their utilization rates. The chi-square test was used to see whether users
of these drugs were different from non-users in their rates of in-hospital mortality. Survey linear
regression was used to explore the effect of utilization of these drugs on LOS. All the visits were

x

weighted to get national estimates. All of the analyses were carried out with SAS 9.3 statistical
package.
RESULT: A total of 1,771 visits (weighted frequency = 6.1 million) by patients were selected
for this study. Both anti-platelet agents and beta-blockers were shown to have a positive trend
across the years. Age, sex, chest pain, triage, using an ambulance, and metropolitan region were
all found to be significant predictors of either antiplatelet agent or beta-blocker utilization. Use
of beta-blockers was associated with lower in-hospital mortality. Neither drug class had an effect
on LOS. Finally, patients who were treated in EDs with computerized guideline reminders were
twice as likely to get an antiplatelet agent, but this was not seen with beta-blockers.

CONCLUSION: This study displayed a positive pattern across the years in the use of
antiplatelet agents and beta-blockers given to older AMI patients. It also showed that age, sex,
and other important variables were significant predictors of their utilization. The use of betablockers yielded lower in-hospital mortality. Finally, the use of ED reminders increased
antiplatelet agent utilization.
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CHAPTER 1
Introduction

Acute Myocardial Infarction Statistics
Heart disease is the number one cause of death in the United States; accounting for
617,000 deaths in 2008.1 Almost 1.2 million older adults, defined as those adults aged 65 years
and older, were discharged from a hospital with heart disease in 2008-2009. Approximately half
of those were discharged with acute myocardial infarction (AMI).2-3 Older adults represent about
13% of the US population, yet account for 60% of hospital discharges for AMI and almost 90%
of AMI in-hospital deaths.3-4 Cardiovascular morbidity and mortality rates rise even more rapidly
in patients 75 years or older.5
Despite the high prevalence of AMI morbidity and mortality in the older adult
population, limited randomized clinical trial data is available to guide their care.5 Although
explicit age-based exclusions in clinical trials have become less frequent since 1990, age-based
exclusions still appear.6-8 Even when age-based exclusions are eliminated from these clinical
trials, implicit age-based exclusions are still a concern.9 For example, physician/investigator
preference or the types of sites involved in the recruitment process may create implicit exclusion
criteria that affect the type of patients enrolled, which may in turn affect the generalizability of
the findings.9
AMI Treatment Timeliness
AMI treatment is a timely matter, so delay in evidence-based acute therapies may put
patients at risk.10 Hence, there is emphasis in the literature on the importance of initiating AMI
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treatment in the emergency department (ED).11-12 The ED is considered to be a critical setting for
measuring AMI care since therapies started in the ED are more likely to be continued during
hospitalization with a lasting impact on patient outcomes.11-12 The Institute of Medicine has
identified the ED as the part of the health care system in most need of improvement.13 The ED
faces a lot of challenges like boarding of admitted patients in the ED, crowding, and ambulance
diversion. AMI is considered an ideal disease for studying ED quality of care since it is initially
treated in the ED and its therapies are time-sensitive and may impact mortality.12,14 Despite its
importance, quite few resources have been directed at studying AMI care in the ED.12
AMI management in the ED is related to the “3 T’s”—triage, treatment, and timeliness of
specialty consultation.10 Initial triage effectiveness governs patient outcomes because empiric
therapy often will be started (e.g. aspirin) and patients will be risk stratified. It is challenging to
triage patients in the ED, as it has to be done in a short time period with limited information.10
Triaging older patients is even more challenging since they frequently present with atypical
symptoms like no chest pain, dizziness, and shortness of breath, often called a silent MI.15
Receiving care by a multidisciplinary specialist team in the ED (i.e. primary care physician,
emergency medicine physician, cardiologist, and an ED nurse) is considered to be a class Ib
recommendation in the American Heart Association (AHA) guidelines; however, it is not always
feasible.16 In this same recommendation, it is also suggested to have written protocols for
triaging and managing AMI patients in the ED.16 Part of these protocols provide the content of
the admitting orders and must indicate that aspirin and a beta-blocker were given in the ED, and
if not, what was the reason.16

2

AMI Guidelines
A large body of evidence supports the early treatment of AMI with antiplatelet agents and
beta-blockers.17-23Treatment with early administration of beta-blockers is becoming more
controversial, specifically intravenous (IV) beta-blockers.24-26 It has been shown that the early IV
administration of a beta-blocker to patients who are hemodynamically unstable or show signs of
heart failure may cause cardiogenic shock.26 The early administration of an oral beta-blocker is
still considered safe and recommended.20,24 In this case, practice guidelines are considered to be
the best tool to guide health professionals’ decisions on AMI treatment by utilizing the strongest
body of evidence from randomized clinical trials (RCTs) and large observational studies.
The American College of Cardiology and the American Heart Association (ACC/AHA)
have used a joint committee since 1980 to guide AMI treatment and other cardiovascular
diseases.27 Approximately every two years they publish a new guideline or update one of the
existing guidelines.27-34 Since 2006, they started publishing performance measures for AMI
treatment. An update of these measures was published in 2008.35-36 These performance measures
aim to assist in the measurement of AMI care quality and increase the uptake of AMI
guidelines.35 In the 2006 performance measures, beta-blockers were recommended to be given
upon ED arrival; however, this recommendation was omitted from the 2008 update.36 They argue
that since there is a distinction between IV beta-blockers and oral beta-blockers and there is a list
of patient factors that need to be checked before administering a beta-blocker, early betablockers were not fit to be a performance measure because of the complexity of its
implementation.36
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AMI Initiatives
AMI is one of the most extensively studied medical condition in the literature.37 In the
last two decades, AMI mortality decreased by 33%, which is believed to be the result of
improved AMI treatment.38 Numerous quality improvement (QI) initiatives and AMI registries
contributed to this improvement by enabling the provision of consistent care and the quick
adoption of clinical advances.38 These initiatives aided in the constant measurement of AMI
quality of care by creating continuous opportunities for improvement.38 One of the most wellknown AMI registries is the Global Registry of Acute Coronary Events (GRACE). It is a
prospective observational project aimed to improve the acute and long-term care in AMI. Patient
data has been collected in 14 countries since 1999.39
There are many US-based QI initiatives and AMI registries. A well-known governmental
QI initiative is the Cooperative Cardiovascular Project (CCP). It was initiated in 1992 by the
Health Care Financing Administration (HCFA, now the Centers for Medicare and Medicaid
Services) to benefit Medicare patients.40 It is a nationwide program that aims to improve quality
of AMI care received by Medicare beneficiaries.40 The American College of Cardiology (ACC)
has developed a program called Guidelines Applied in Practice (GAP) with a goal of facilitating
the use of the ACC/AHA guidelines in practice.41 The American Heart Association (AHA) has a
similar initiative to GAP called the Get With the Guidelines (GWTG) initiative. The ACC and
the AHA share the same goals in their QI initiatives.38 The National Cardiovascular Data
Registry (NCDR) had the initiative in year 2007 to merge two large AMI registries into one large
national AMI registry.38 The National Registry of Myocardial Infarction (NRMI) and “Can
Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early
Implementation of the ACC/AHA Guidelines” (CRUSADE) QI initiative merged into one
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registry called the Acute Coronary Treatment and Intervention Outcomes Network (ACTION).38
Afterwards, the NCDR still perceived a need for a more unified registry; hence, it facilitated a
merger in 2008 between the ACTION registry and the GWTG initiative to create the ACTION
Registry-GWTG (AR-G).38
Conceptual Framework
When studying the quality of care in a certain disease (e.g. AMI), it is best to use a
framework that has been developed to measure and assess clinical practice. The most utilized
and widely accepted framework in this area is the Donabedian model, or the structure-processoutcome model, a simple and persuasive model that combines all aspects of health care.42
To best understand and use the Donabedian model, it is important to explain this triad
“structure-process-outcome” in more detail. Structure in this model represents material
resources, human resources, and organizational characteristics, such as the presence of teaching
and research functions and integrated computer systems. Process, on the other hand, constitutes
all the activities performed in patient health care, like diagnosis, treatment, and prevention.
Outcome is the end result of a health care service or activity and reflects any desirable or
undesirable change in the patient. Outcomes may include clinical, economic, and humanistic
outcomes.42
There are certain rules or conditions that govern how we use this model. It is important to
know that structure, process, and outcome are not considered aspects of quality. We can only
infer that quality is good or bad by the information available to us. Another pivotal rule is that
without a predetermined relationship between the structure, process, and outcome, no inferences
can be made. This relationship should be supported by well-established evidence. The stronger
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this relationship is the stronger the inferences being made. Finally, this model is developed to
assess clinical practice, so it may not work as well in other settings.42
Choosing the right outcome to assess clinical care is a pivotal step. Donabedian provided
some guidelines to follow when choosing the outcome. The outcome must be relevant,
achievable by good care, attributed to health care, and available to collect.42 Also, it is important
to consider the magnitude and duration of the outcome, and when tracking the consequences of
taking an action, it is also important to track the consequences of not taking action.42
Overview of the study
This study is designed to assess the acute pharmacological treatment given in the ED to
older adults with AMI from a “structure-process-outcome” approach. The structure component is
the ED computerized guideline reminders. The process component is the utilization of antiplatelet agents and beta-blockers in the ED. Finally, the outcome component is in-hospital
mortality and length of hospital stay. Our study is an exploratory study that is aimed to generate
hypotheses for future study.
Significance
This study gives national estimates about older adult AMI care in the ED from 1992 to
2010, which is the first to capture this long period of time of ED AMI care for older adults.
Using the Donabedian model as a conceptual framework gave a holistic view of AMI care in
older adults. The impact of having a computerized ED guideline reminder on the usage of
antiplatelet agents and beta-blockers in the ED was evaluated, which is also a first. It also did
describe the percentages of antiplatelet agents and beta-blockers used only in the ED, which was
only done in few studies. Our study attempted to see the effect of AMI care in the ED on hospital
outcomes, like in-hospital mortality and LOS. Finally, this study may help in increasing the
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awareness of the ED health care professionals of older adults AMI care and the importance of
incorporating computerized clinical decision support (CCDS) systems in the ED to remind health
professionals about using guideline recommended therapies.
Study Objectives
This study had four primary objectives.
1. Examine the temporal trend in the ED use of anti-platelet agents and beta-blockers in
older adults with AMI in the US from 1992 to 2010
2. Explore the association between a variety of predictor variables (demographic, clinical,
visit, and hospital variables) and the ED use of anti-platelet agents and beta-blockers in
older adults with AMI
3. Evaluate the association between the ED use of anti-platelet agents and beta-blockers
in older adults with AMI and the rate of in-hospital mortality and length of hospital stay
4. Evaluate the association between the use of ED computerized guideline reminders and
the ED utilization of anti-platelet agents and beta-blockers in older adults with AMI
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CHAPTER 2
Literature Review

AMI overview
AMI definition and classification
The literal meaning of myocardial infarction is the death of cardiac myocytes caused by
prolonged ischemia.1 The World Health Organization (WHO) defined myocardial infarction in
the Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) project
published in 1994;2 however, this definition was updated by the European Society of Cardiology
(ESC) and the American College of Cardiology (ACC) in 2000 because the WHO definition
erroneously diagnosed patients with non-myocardial infarction even when actual cardiac damage
had occurred.1,3 The updated definition of AMI is summarized in Figure 2.1.
Criteria for acute, evolving, or recent MI
Either one of the following criteria satisfies the diagnosis for an acute or recent MI:
(1) Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of
biochemical markers of myocardial necrosis with at least one of the following:
(a) ischemic symptoms;
(b) development of pathologic Q waves on the ECG;
(c) ECG changes indicative of ischemia (ST segment elevation or depression); or
(d) coronary artery intervention (e.g., coronary angioplasty).
(2) Pathologic findings of an acute MI.
Figure 2.1: AMI definition of the European Society of Cardiology and the American
College of Cardiology (Adapted from Ref. 1)
MI: Myocardial infarction; CK-MB: Creatine kinase-MB; ECG: Electrocardiogram

12

Acute Coronary Syndromes (ACS) encompass a number of cardiovascular presentations
which differ by the extent and duration of coronary occlusion, and include unstable angina (UA),
non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction
(STEMI).1 Both NSTEMI and STEMI are known collectively as AMI.5 Classification of AMI is
made according to the changes found in the ECG. Figure 2.2 illustrates the differences between
the two.4 AMI may be further classified according to the pathologic Q-waves. Patients with
STEMI are more likely to have Q-waves in their ECG findings, or Q-wave MI (QMI). NSTEMI
patients are less likely to have them, thus non-Q-wave MI (NQMI).5 The pathophysiology of
ACS starts with the rupture of an atherosclerotic plaque followed by platelet adherence,
aggregation, and activation of the clotting cascade, which will end in the formation of a clot
filled with fibrin and platelets. 4

Figure 2.2: Differences in ECG between STEMI and NSTEMI (Adapted from Ref. 4)
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AMI diagnosis and risk stratification
The typical symptom of AMI is chest pain, or more formally a midline anterior anginal
chest discomfort that may radiate to the shoulder, down the left arm, to the back, or to the jaw.
There are other symptoms that may accompany chest pain, like nausea, vomiting, and shortness
of breath. There are no specific signs of AMI; hence, on physical examination, there will be no
suggestive signs of AMI. The main diagnostic procedure in detecting AMI is the 12-lead ECG,
followed by a laboratory test of troponin and CK-MB, which are biochemical markers of
myocardial cell death, to confirm AMI diagnosis. The 12-lead ECG should be done within 10
minutes of patient’s presentation in the ED.4 More recent studies are recommending the 12-lead
ECG to be done in the ambulance by the EMS staff.6 It is important to check the troponin and
CK-MB level at least 3 times (in the ED, at 12 hours, and at 24 hours) because some patients
may present to the ED with values below the level of detection. At 12 or 24 hours, they may
have positive values of troponin or CK-MB.4 Figure 2.3 illustrates CK-MB and troponin levels in
the blood across the days around AMI.7
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Figure 2.3: Troponin and CK-MB levels in AMI patients
Risk stratification in AMI is very important, as patients will be treated according to their
risk stratification.4 Patients are stratified according to their symptoms, medical history, ECG
readings, and troponin or CK-MB levels. Patients experiencing a STEMI are considered to be at
high risk of mortality. On the other hand, when patients are experiencing a NSTEMI, their risk
level is dependent on many factors. The Thrombolysis in Myocardial Infarction (TIMI) risk
score is used to stratify NSTEMI patients4-5,8 and is presented in Figure 2.4. Low risk patients
are usually monitored either in the ED or in a general ward. If values of troponin and CK-MB are
still negative, they could be discharged. Moderate risk patients will be admitted either to the
coronary care unit (CCU) or the step-down unit (SDU) to be monitored and treated. High risk
patients should get early coronary angiography, which will be done in the cardiac catheterization
laboratory.4
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Past medical history
Clinical presentation
Age ≥ 65 years
ST- segment depression( ≥0.5)
≤ 3 risk factors for CAD
2 episodes of chest discomfort within the
past 24 hours
 Hypercholesterolemia
Positive
biomedical
marker
for
infection.
 HTN
 DM
 Smoking
 Family history of positive CHD
Known CAD (≥50% stenosis of coronary
artery)
Use of aspirin within the past 7 days
Using the TIMI Risk Score
One point is assigned for each of the seven medical history and clinical presentation
findings.
The score (point) total is calculated, and the patient is assigned a risk for experiencing
the composite end point of death, myocardial infarction, or urgent need for
revascularization as follows
High Risk
Medium Risk
Low Risk
TIMI risk score 5 – 7
TIMI risk score 3 –4
TIMI risk score 0 – 2
points
points
points
Other Ways to identify High – Risk Patients
Other findings that alone or in combination may identify high – risk patients:
 ST- segment depression.
 Positive biomedical marker for infection.
 Deep symmetric T- wave inversions (≥ 2mm).
 Acute heart failure.
 DM.
 Chronic kidney disease.
 Refractory chest discomfort despite maximal pharmacotherapy for ACS.
 Recent MI within the past 2 weeks.
Figure 2.4: TIMI score for NSTEMI (Adapted from Ref. 4)
Risk factors of getting an AMI are actually the same factors that are responsible of
developing and progressing of atherosclerosis.9 There are established risk factors which have
clear evidence that their modification is associated with a decrease in the risk of cardiovascular
disease (CVD).3 These include dyslipidemias (high Low-Density Lipoprotein (LDL) or low
High-Density Lipoprotein (HDL)), smoking, and hypertension.3,9 There are other established risk
factors, but it is less clear if their modification is associated with a decrease in the risk of CVD.3
These include diabetes mellitus, obesity, and physical inactivity.3,9 More recently, there are
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emerging risk factors, which are mostly inflammatory markers like C-reactive protein and
interleukins, but it is not clear whether their modification is associated with a decrease in the risk
of CVD.3
Most AMI complications are life-threatening. The larger the infarct area, the higher the
chance of experiencing complications. Also, the more ruptured plaques and the more coronary
arteries involved, the worse the prognosis will be.10 The most life-threatening complication is
cardiogenic shock. Almost 2-6% of AMI patients experience it. Patients presenting with STEMI
are more likely to develop cardiogenic shock compared to patients with NSTEMI.11-12 Mortality
almost reaches 60% when patients experience cardiogenic shock.13 Other complications are
pericarditis, ventricular and atrial tachyarrhythmia, venous thromboembolism, heart block,
valvular dysfunction, left ventricular (LV) free-wall rupture, bradycardia, stroke secondary to LV
thrombus embolization, and heart failure. Many patients experience those complications even
before reaching the hospital. For example, almost 25% of patients with AMI die before reaching
the hospital because of ventricular fibrillation.14
AMI treatment
AMI acute interventional treatment
Time is a crucial factor in AMI treatment. Minutes can mean the difference between a
patient’s death and survival. Early restoration of blood flow to prevent further expansion of the
infarct area is one of the most important short-term treatment goals.4 This can be achieved either
by fibrinolysis or primary percutaneous coronary intervention (PCI). According to the
ACC/AHA recommendations, STEMI patients should receive fibrinolysis within 30 minutes or
primary PCI within 90 minutes.15 Both timely fibrinolysis and timely PCI are considered to be
quality performance measures. Time to fibrinolysis is called “door-to-needle-time,” and time to
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PCI is called “door-to-balloon-time”.15 STEMI patients should be transferred directly from the
ED to the cardiac catheterization unit to undergo a coronary angiography with either a balloon
angioplasty, placement of bare-metal stent, or drug-eluting intracoronary stent.4 PCI has been
proven to be safer and more effective than fibrinolysis and also has fewer contraindications and
side effects.15-17 Patients may undergo rescue PCI during their hospitalization if the fibrinolysis
was unsuccessful, which is superior to repeated fibrinolysis.18 High risk NSTEMI patients should
also be revascularized early either by a primary PCI or coronary artery bypass surgery
(CABG).5,17
AMI acute medical treatment
Early pharmacotherapy is a pivotal component of AMI patients’ treatment. Both STEMI
and NSTEMI patients receive the same pharmacological treatment. The standard treatment that
should be given in the ED is intranasal oxygen (if oxygen saturation was less than 90%),
morphine (for anginal pain), sublingual nitroglycerin, aspirin, a beta-blocker, and anti-coagulants
(ex. unfractionated heparin or enoxaparin).5,15 It has been well established that both aspirin and
beta-blockers improve survival.19-20 Hence, it was recommended that aspirin should be given as
early as within 10 minutes of experiencing chest pain.21 Beta-blockers should also be given early
either IV or orally.5-15 There has been some controversy around the IV administration of betablockers because of the risk of cardiogenic shock when given to hemodynamically unstable
patients.22-23 Early administration of aspirin and beta-blockers are both considered Class I
recommendations in the ACC/AHA guidelines.5,15,23 Early administration of aspirin prevents
thrombotic occlusion during the PCI procedure.21
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AMI secondary prevention
The main therapeutic goal in AMI treatment is to prevent ventricular remodeling, which
will lead to cardiac failure and ultimately death.4,24 Drugs that prevent ventricular remodeling
improve survival. 24 Both beta-blockers and angiotensin converting enzyme (ACE)-inhibitors are
well established to improve survival because both of them help prevent ventricular remodeling.20,
25-27

Both should be continued indefinitely after their initiation in the hospital.5,15,23 Also, aspirin

should be continued indefinitely after AMI, because it decreases the risk of death, recurrent MI,
and stroke.5,15,19,23 Statins could be started in the hospital regardless of patient’s LDL cholesterol
levels and also continued indefinitely because of their benefits in preventing total mortality, CV
mortality, and stroke.5,28-29 Finally, most patients should also take clopidogrel as secondary
intervention, but the duration of treatment differs according to how the patient was managed in
the hospital.4 It should be administered indefinitely if the patient has aspirin allergy. It should
only be administered for 9-months post AMI if the patient was managed medically and for 12months if the patient underwent PCI.4
Older adults
Challenges of treating AMI in older adults
Chronological age alone has been shown to be an independent predictor of medical
decision-making potentially impacting clinical care.30 One of the consequences of advanced age
in AMI is the atypical clinical presentation of AMI in older adults, such as shortness of breath,
functional and cognitive decline, fatigue, and non-diagnostic electrocardiogram (ECG). More
importantly, chest pain, which is the landmark symptom of AMI, is seen less commonly in this
population.31,32 This may lead to difficulty in facilitating early triage and diagnosis, which will in
turn lead to a delay or underuse of recommended care.31 Additionally, older adults are known to
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have a higher prevalence of comorbid conditions, which may further complicate their care.31
Patients presenting with comorbidities cause a challenge to physicians because they need to
consider the contraindications and drug interactions and also weigh the risks and benefits before
prescribing any drug. Another possible problem that may lead to the delay of care of older adults
is the potential for inappropriate risk stratification. Since most older adults have a low prevalence
of traditional, widely known, risk factors like ischemic heart disease, smoking, and family
history of cardiovascular (CV) diseases, their risks of negative outcomes may be underestimated
leading to a lower estimated urgency in care.33
It is important to mention that advanced age in and of itself is considered to be an
independent predictor of increased mortality after AMI.34 There are several physiologic and
structural changes in older adults that may yield negative outcomes.35 These include an increase
in LV mass index, abnormalities of LV function, and decrease in systemic vascular
compliance.36-42 Furthermore, there may be an increase in coagulation factors (VII, VIII, and IX)
compared to the anticoagulation factors (antithrombin III and Protein C) that may lead to a
greater risk of thrombosis, hence a greater infarct size.42 Older adults have increased risk of
experiencing in-hospital AMI complications including congestive heart failure, atrial fibrillation,
cardiogenic shock, and complete heart block.30 All of these complications may contribute to a
longer hospital stay. As one study reported, older adults have hospital stays almost two times
longer than younger adults.33 Another study found that the older the patient is the higher the
mortality risk from AMI.30
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Challenges of pharmaceutical care in older adults
Older adults (i.e., those ≥65 years) represent about 13% of the US population yet account
for 32% of all prescription drugs.43,44 Older patients are more likely to experience adverse drug
events (ADEs). This is due to several factors, including overuse of medications, medication
errors, non-adherence to medications, and inappropriate drug use.45 It has been reported that the
incidence of ADEs in older patients varied from 5% to 35%, depending on the method used to
define ADEs.46,47 ADEs may result in the need for additional medications, disability, decrease in
quality of life, hospitalization, or death.48 One way of preventing ADEs in older patients is to
avoid the use of potentially inappropriate medications (PlMs).49
PIMs are drugs that have a poor risk-benefit profile due to aging-related physiologic or
pharmacokinetic changes or have been correlated with poor outcomes in older patients.49-51
Specific criteria for appropriateness of drugs in older adults were developed to identify these
PIMs. The National Committee for Quality Assurance (NCQA) established a list of drugs to be
avoided in the elderly (DAE) as part of the Healthcare Effectiveness Data and Information Set
(HEDIS) measures.52 The NCQA HEDIS measures are based on the Beers list and the 2003
update of that.53,54 In 2012, the American Geriatrics Society (AGS) updated Beers criteria for
PIMs use in older adults.55
Prescription of PIMs in older patients is highly prevalent ranging from 12% in
community-dwelling elderly to 40% in nursing home residents.56 PIMs in older adults are
associated with drug-related problems like hip or femur fracture, falls, hypoglycemia, as well as
an increase in overall health care costs.57 Older adults are more vulnerable to PIM exposure in
the ED because of the patients acuity and physician unfamiliarity with the patient.58
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ED utilization by older adults
Older adults (≥65 years) are the fastest growing segment in the US population.59,60 As
with any other health service, ED utilization by older adults will increase with this increase in
population.61 It was found in a study using the NHAMCS database that older adults’ rate of ED
utilization increased by 34% from 1993 to 2003.61 This will increase the problem of ED
crowding, which will further complicate the ED management of the older adults.61 It will also
increase the problem of ED boarding, ED boarding happens when patients are admitted to the
hospital but are still awaiting their bed space, so they get boarded in the ED corridors until they
get admitted, especially since most older adults coming to the ED will eventually be admitted to
the hospital.59,60,62 ED crowding plus ED boarding may cause a delay in treatments and decline in
the quality of care provided.62 Sadly, older adults may be significantly affected by this delay
since they present with more severe conditions, more comorbidities, and higher levels of
acuity.63 It was found that older adults are five times more likely to get a high-priority triage than
younger adults.62,64
The time from ED arrival to ED disposition is longer in older adults compared to younger
adults. Elderly patients were three times more likely to stay more than 1 day in the ED than
younger patients (14.0% vs. 4.7%, p < 0.001).63 This may be attributed to the difficulty older
adults face in trying to explain their clinical condition or history, plus the ambiguity of their
physiological signs or symptoms.63,65 An older adult ED visit costs twice more than a younger
adult because of higher drug charges, higher treatment charges, and more diagnostic
procedures.63,66-67 The old-old (≥85) age group was found to have higher ED utilization.63,68 This
was due to their lack of social support, poor living arrangements, and limited mobility.63
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Previous investigations
ED treatment of AMI
Few studies have documented ED utilization of aspirin and beta-blockers in AMI
patients.69-76 A couple of studies defined drug use to be limited to ED administration only.69-70, 7476

Some of those studies considered that as a limitation because they were not able to capture pre-

hospital use of aspirin.70,74,76 Another study was only interested in the ED use of beta-blockers, so
they did not need information about pre-hospital administration of drugs, because beta-blockers
are not given by paramedics.75 Interestingly, in a Brazilian study, the documented average length
of stay in the emergency room was 6.7 days.69 This suggests that emergency rooms there may be
treated like an official ward. Hence, use of drugs in the ED in that study may not mean early use
because a drug may have been started on the 5th day of the stay in the ED. The other studies
documented drug administration to be in the ED or 24 hours before ED arrival.71-73 Those studies
aimed to capture aspirin administration by the EMS or by the patient at home.
Several studies had detailed clinical information about study patients.71-73,75-76 Patients
who had contraindications to aspirin and beta-blockers could thus be excluded. Their utilization
percentages were more accurate in comparing percentages across studies (see Table 2.1).
Utilization varies greatly between studies primarily because they were done in different years.
Earlier years had lower utilization rates compared to more recent years. The definition of
administration and the depth of their clinical information can all affect utilization rates. The
Brazilian study included an educational intervention for the ED staff about the implementation of
clinical guidelines, so pre-intervention utilization rates and post-intervention utilization rates
were available.69 In Table 2.1, the pre-intervention rates are reported for the sake of consistency
with other studies. Only one study was nationally representative, but it was almost 10 years old.74
23

Finally, only one study was specifically designed to study older adults, but the focus was betablocker administration.75 All these studies examining ED treatment of AMI are summarized in
Table 2.1.
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Table 2.1: Summary of studies documenting ED utilization of aspirin and beta-blockers in AMI patients
Reference

Study setting

Time frame
2005-2006

Total no. of
AMI patients
78

Mean age or
Median age
Not mentioned

Escosteguy (2011)69

1 Hospital in
Brazil

Takakuwu (2010)70

1 Hospital in
Pennsylvania

1999-2002

4,470

52.2 ± 15.8

Tsai (2010)71

58 Hospitals
across 20 states

2003-2006

3,819

65 (54 – 76)**

Vinson (2007)72

5 Hospitals in
California and
Colorado

2000-2002

2,215

74.3 ± 13.6
(women)
66.8 ± 11.9 (men)

Magid (2005)73

5 Hospitals in
California and
Colorado
NHAMCS

2000-2002

2,215

1998-2004

1,492

ASA: 1,639
(80.5%), BB: 552
(60.3%)
ASA: 596 (40%),
BB: 231 (17%)

Vega (2006)75

1 Hospital in
Pennsylvania

2001-2003

385

74.3 ± 13.6
(women)
66.8 ± 11.9 (men)
62 (aspirin
users)***
64 (BB users)
68 ± 14

Saketkhou (1997)76

4 Hospitals in
Rhode Island

1994

2,383

66 ± 14

ASA: 712 (30%),
BB: NA

Pham (2007)74

N(%) treated
with ASA&BB
(Pre-intervention)
ASA: 68 (87%),
BB: 40 (51%)
(Post-intervention)
ASA: 63 (96%),
BB: 62 (94%)
ASA: 2,498
(56%), BB: NA
ASA: 2,980
(83%), BB: 945
(55%)
ASA: 1,639
(80.5%), BB: 552
(60.3%)

ASA: NA, BB:
129 (47%)

Conclusion
ED educational
interventions
increased ASA&
BB utilization

ASA utilization
was not affected
by age, race, sex
Utilization of
ASA&BB was
not ideal in ED
ASA&BB
utilization was
suboptimal in
ED
Older adults
receive less
ASA&BB in ED
ED use of ASA
&BB was below
expected goals
Older STEMI
patients receive
less BB in ED
ASA in the ED
is underutilized

*BB = beta-blockers, **Median was provided with IQR, ***SD was not provided, ED= Emergency department, AMI= Acute myocardial infarction
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Inpatient treatment of AMI
Several studies have documented inpatient use of aspirin and beta-blockers in AMI
patients.77-90 Two studies looked at the trend of aspirin and beta-blockers utilization across time
(1992-2002) with both noting an upward trend in utilization.77,81 Other studies were carried out
to examine the effect of sex or race on aspirin or beta-blocker utilization.79,81,82,90 Their results
varied. One study was interested to know if diabetic AMI patients had different utilization rates
of aspirin compared to non-diabetic AMI patients.83 The authors found that patients who had
diabetes were less likely to get aspirin compared to patients who did not have diabetes.83 Another
study examined the effect of type of insurance on the utilization of aspirin and beta-blockers.88 It
found that patients in health maintenance organizations were more likely to receive aspirin and
beta-blockers than fee-for-service patients.88
Most of the studies examined the effect of age on utilization of aspirin and beta-blockers,
and all hypothesized older patients were less likely to receive aspirin or beta-blockers.80,84-87,90
All studies found evidence supporting their hypothesis. Utilization rates in all of these studies
were very similar. Aspirin rates were generally above 80%, and beta-blockers were between 60%
and 70%.77,79-84,88 Some of the older studies (1990-1996) had lower beta-blocker utilization
rates.85-87, 89-90 During that time period there was not much emphasis on beta-blocker use for
secondary prevention in AMI patients. Studies examining inpatient use of aspirin and betablockers are summarized in Table 2.2.
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Table 2.2: Summary of studies documenting inpatient utilization of aspirin and beta-blockers in AMI patients
Reference

Study setting

Data years

Total no. of
AMI patients
1,475

Mean age or
Median age
80.8 ± 5.1*

% treated with
ASA & BB
ASA: 87, BB: 70*

Gottlieb
(2007)77

25 Hospitals in
Israel

1992-2002

Marti
(2007)78
Mehta
(2006)79

1 Hospital in
Spain
GUSTO and
ASSENT trials

2000-2004

Age range (80-97)

ASA: 55, BB: 4

1992-2000

Not
mentioned
32,419

61.1±12.2 (Whites)
57.0±12.1 (Blacks)

102 hospitals in
14 countries

1999-2002

24,165

50% of the sample
are 55-74 years**

Vaccarino
(2005)81

NRMI†
database

1994-2002

598,911

66.4 (White men)
74.0 (White women)
61.3 (Black men)
67.3 (Black women)

Blomkalns
(2005)82

CRUSADE††
database

2000-2002

35,875

68 (56-78) †††

Collinson
(2004)83

PRAIS-UK‡
database

1998-1999

1,046

66 ± 12

(Whites)
ASA: 93.2, BB: 80.8
(Blacks)
ASA: 93.7, BB: 82.6
(age = 65-74)
ASA: 92, BB: 78
(age ≥85)
ASA: 88, BB: 65***
(White men)
ASA: 84, BB: 67
(White women)
ASA: 79, BB: 63
(Black men)
ASA: 84, BB: 68
(Black women)
ASA: 78, BB: 65
(Males)
ASA: 91.6, BB: 77.7
(Females)
ASA: 89.6, BB: 75.9
(Diabetics)
ASA: 81, BB: NA
(non-Diabetics)
ASA: 88, BB: NA

Avezum
(2005)80
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Conclusion
ASA&BB utilization
had a positive trend
across 1992-2002
very low use of ASA
&BB in patients ≥85
ASA&BB utilization
was not different
between white and
black patients
ASA&BB utilization
was suboptimal in
older adults
Use of ASA&BB did
not vary according to
race and sex

Use of ASA&BB did
not vary according to
sex
Diabetics had lower
ASA utilization than
non-diabetics

Stern
(2004)84

26 Hospitals in
Israel

2000

2,133

70 ± 2 (65-74)
81 ± 5 (≥75)

(age = 65-74)
ASA: 96, BB: 76
(age ≥75)
ASA: 95, BB: 64
(age = 65-69)
ASA: 78, BB: 55
(age ≥85)
ASA: 64, BB: 38
ASA: 97, BB: 44

Rathore
(2003)85

CCP‡‡
database

1994-1996

146,718

76 ± 7

Ruiz-Bailen
(2002)86

119 Hospitals in
Spain

1995-2001

17,761

65.2 ± 12.3

Mehta
(2001)87

CCP‡‡
database

1994-1996

163,140

Not mentioned

Soumerai
(1999)88

20 Hospitals in
Minnesota

1992-1996

2,340

50% of the sample
are ≥75 years

Marciniak
(1998)89
Stone
(1996)90

Hospitals in AL,
CN, IO, WS
TIMI III ‡‡‡
Registry

1992-1996

23,535

75.3

(age = 65-69)
ASA: 84, BB: 52
(age ≥85)
ASA: 69, BB: 33
(HMO)
ASA: 88, BB: 73
(FFS)
ASA: 83, BB: 62
ASA: 84, BB: 47

1990-1993

3,318

63.8

ASA: 82, BB: 45

Older adults are less
treated with
ASA&BB than
youngers adults
Older adults are less
treated with
ASA&BB than
youngers adults
ASA&BB were
underutilized in
older adults
Older adults had
lower utilization
rates of ASA&BB
HMO patients were
more likely to get
ASA&BB than FFS
patients
ASA&BB were
suboptimaly used
Older adults are less
treated with ASA&
BB than younger
adults

*Numbers are of most recent year (2002), **No mean age was reported, ***NRMI= National Registry of Myocardial Infarction, †Youngest and oldest groups
were only reported, ††CRUSADE= Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the
American College of Cardiology/American Heart Association Guidelines initiative, ††† Median and IQR, ‡ PRAIS-UK= Prospective Registry of Acute Ischemic
Syndromes in the United Kingdom, ‡‡ CCP= Cooperative Cardiovascular Project, ‡‡‡ TIMI= Thrombolysis In Myocardial Infarction, AMI = Acute myocardial
infarction, BB = beta-blockers
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AMI treatment effect on mortality
Several studies examined the effect of aspirin and beta-blockers on mortality, but none
looked at their effect on length of hospital stay (LOS).91-100 Most of studies were interested in the
effect of aspirin and beta-blockers on in-hospital mortality.91,92,95,96,98,99 The results from these
studies varied. A couple of studies looked at the effect of aspirin on 30-day mortality postAMI.94,100 Both found that aspirin significantly lowered 30-day mortality.94,100 Another studies
looked at the effect of aspirin or beta-blockers on mid-to-long-term mortality. One study
examined the effect of beta-blockers on midterm mortality (mean follow-up almost 2 years) and
found that patients receiving a beta-blocker had a lower midterm mortality.93 The other study
evaluated 1-year mortality post-AMI and found that both aspirin and beta-blockers
administration resulted in lower 1-year mortality rates.97
Some studies looked at the cumulative effect of all acute treatment given to the patient on
in-hospital mortality.95,98 One examined the cumulative effect of acute medical treatment
(aspirin, beta-blockers, oral anti-coagulants, and oral anti-platelets) and found that patients
treated acutely with these drugs had lower in-hospital mortality.95 The other examined the
cumulative effect of both acute medical and interventional treatment (e.g. PCI) finding that
patients had lower in-hospital mortality rates when they were treated acutely by those drugs.98
Several studies were interested in the effect of acute treatment of aspirin and betablockers on mortality, which was defined by most studies to be administered in the first 24
hours.91,92,95,96,98,99 These studies all evaluated the effects of aspirin and beta-blockers on inhospital mortality, which may explain why they only looked at acute treatment. All these studies
are summarized in Table 2.3
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Table 2.3: Summary of studies documenting the effects of utilization of aspirin and beta-blockers in AMI patients on mortality

2002-2008

Total no. of
AMI patients
6,826

Mean ± SD age or
Median (IQR) age
65.3 ± 14.7*

2000-2009

156,677

66.4 ± 14.7

2002-2008

77

86 ± 4

1994-1995

120,032

76.7 ± 7.4

NRMI database

1990-2006

2,515,106

65.5 ± 14 †††

MITRAPLUS‡‡
German registry
9 provinces in
Canada
CRUSADE
database

1994-2005

17,809

65.3 ± NA

1999-2001

4,627

2001-2003

56,963

46% of the sample
is less than 65 years
58% of the sample
is older than 65

CCP database

1994-1995

58,165

75.1± NA

CCP database

1992-1993

10,018

NA

Reference

Study setting

Data years

Filardo (2011)91

Radcliff (2010)94

14 Hospitals in
Texas
GWTG-CAD
database***
1 Hospital in
Japan
CCP database

Peterson (2008)95
Wienbergen
(2007)96
Yan (2006)97

Medina (2011)92
Kashima (2010)93

Alexander
(2005)98
Krumholz
(1999)99
Krumholz
(1995)100

Effect of aspirin
on mortality
OR=0.37 (95%
CI: 0.22-0.65)
OR=0.88 (95%
CI: 0.76-1.02)**
NA

Effect of BB
on mortality
OR=0.24 (95%
CI: 0.11-0.52)
OR=0.87 (95%
CI: 0.77-0.98)
HR=0.34 (95%
CI: 0.12-0.99) †
NA

OR=0.57 (95%
CI: 0.54-0.60) ††
OR=0.980 (95% CI: 0.975-0.984) ‡
for both aspirin and beta-blockers
NA
OR=0.70 (95%
CI: 0.61-0.81)
OR=0.48 (95%
OR=0.72 (95%
CI: 0.36-0.65)
CI: 0.56-0.93)
Acute aspirin and BB associated with
lower rates of hospital mortality (OR
not provided)
NA
OR=0.81 (95%
CI: 0.75-0.87)
OR=0.73 (95%
NA
CI: 0.65-0.82)

*Results of year 2008, **Comparison between (65-79) age group and (<65) age group, *** GWTG-CAD= Get with the Guidelines-Coronary Artery Disease,
†Results of the non-PCI group, †† Results of the community-dwelling older adults, ††† Results of most recent years 2003-2006, ‡This OR represents the effect
of all acute treatment (aspirin, beta-blockers, anti-coagulants, and anti-platelets) on mortality, ‡‡ MITRA= Maximal Individual Therapy of Acute Myocardial
Infarction registry, ‡‡‡ No SD available, the mean age is for the beta-blocker users, CI= Confidence intervals, CCP= Cooperative Cardiovascular Project, OR=
Odds ratio, NRMI= National Registry of Myocardial Infarction, CRUSADE= “Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse
Outcomes with Early Implementation of the ACC/AHA Guidelines”, NA= Not available, SD= Standard deviation
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ED structure effect on AMI treatment
Only two studies evaluated ED structure effects on AMI treatment.101-102 Both studies
used national databases: CRUSADE101 and CCP102. One study conducted a survey on 316
CRUSADE participating hospitals from 2001 to 2003.101 This survey targeted ED physicians and
nurse coordinators to answer certain questions about the ED structure. Only 136 hospitals
(representing 20,856 patients) replied with both the physician and the nurse response. This study
had valuable input about the relationship between ED structure and ACC/AHA guidelines
concordance (ECG within 10 minutes, aspirin and beta-blockers at arrival, use of heparin and
glycoprotein IIb/IIIa inhibitors within 24 hours). They found that the strongest determinant of
guideline concordance was having an ED administration highly committed to quality initiatives
(OR: 1.58, 95% CI: [1.45-1.72]). They also found that having adequate nursing in the ED yields
better concordance with the guidelines (OR: 1.09, 95% CI: [1.04-1.15]) because it allows more
time with each patient. Finally, their most relevant result to the current study is that one of the
main determinants of guideline concordance is having an algorithm, not specified whether it is
computerized or not, available in the ED for AMI care (OR: 1.08, 95% CI: [1.03-1.12]).
The other study was only interested in aspirin and beta-blocker administration.102 It
examined the organizational infrastructure of 44 hospitals in Kansas participating in the CCP
project to see whether organizational infrastructure affects administration of aspirin and betablockers. They found that almost 68% of hospitals have an ED protocol, where 43% of those
protocols specified aspirin and 18% specified beta-blockers. Having protocols that specified
aspirin and beta-blockers in the ED significantly affected beta-blocker administration on
admission (OR: 2.14, 95% CI: [1.25-3.77]), but it did not affect aspirin on admission (OR: 1.31,
95% CI: [0.87-2.00]). They also found that almost 54% of the hospitals had an ED standardized
31

order set where 34% of those sets specified aspirin and 20% specified beta-blockers. Having
those standardized sets in the ED significantly affected aspirin administration on admission (OR:
1.57, 95% CI: [1.01-2.48]), but it did not affect beta-blocker administration on admission (OR:
1.57, 95% CI: [0.87-2.93]). Unlike the previous study, they did not find that having an ED
administration committed to quality was a determinant of aspirin or beta-blocker
administration.102
No studies examined the effect of computerized clinical decision support (CCDS)
systems in the ED on AMI treatment. Several studies have looked at the effect of CCDS in other
disease states and in different settings. 103-106 Few studies have examined the effect of CCDS
system in the ED.107-108 One study used the CCDS system in the ED to screen for HIV. They
found that using the CCDS for this purpose increased the detection rate of HIV and hence helped
in treating undetected HIV cases107 The other study found that when incorporating pneumococcal
vaccination reminders in the CCDS system in the ED, it helped to overcome existing barriers that
the health professionals had towards pneumococcal vaccination.108
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Literature gap and significance
Based on this extensive literature review, most of the studies were not specifically
focused on older adults (>65). Also, very few studies evaluated care in the ED where the AMI
patient is first evaluated and treated. Several studies examined the effect of acute (ED plus
inpatient) AMI care on mortality, but none looked specifically at the effect of ED care on
mortality. None of these studies looked at the effect of ED care on length of hospital stay.
Finally, only two studies looked at the effect of ED structure on AMI care in the ED, but none
looked at the effect of CCDS in the ED on AMI care.
This study will give national estimates about older adult AMI care in the ED from 1992
to 2010. This is the first study to capture this long period of time of ED AMI care for older
adults. This study uses the Donabedian model for quality measurement, which gives a holistic
view of AMI care in older adults. This study will evaluate the impact of having a computerized
reminder to prompt ED staff to use guidelines, on the usage of guideline concordance therapy in
the ED. This study will also reveal the percentages of drugs use only in the ED, which was only
done in few studies. This study will also attempt to see the effect of care in the ED on hospital
outcomes, like in-hospital mortality and LOS. Finally, this study may help increase ED health
care professionals’ awareness of older adults AMI care and the importance of incorporating
CCDS systems in the ED to remind health professionals about using guideline recommended
therapies.
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CHAPTER 3
Methods

Data source
The National Hospital Ambulatory Medical Care Survey (NHAMCS), one of the
databases available from the National Center for Health Statistics (NCHS), was used for this
study. NHAMCS was selected instead of the National Ambulatory Medical Care Survey
(NAMCS) because ED data is only available in the NHAMCS database. NHAMCS includes a
national probability sample of visits to the emergency and outpatient departments of
noninstitutional general and short-stay hospitals in the 50 States and the District of Columbia.1
The survey design is a four-stage probability sampling approach with samples of primary
sampling units (PSUs), hospitals within PSUs, clinics and emergency service areas within
hospitals, and patient visits within clinics and emergency service areas.1 The PSU consists of a
county, a group of counties, county equivalents (such as parishes and independent cities), towns,
townships, minor civil divisions (for some PSUs in New England), or a metropolitan statistical
area (MSA).2 The PSUs are comprised of a probability subsample of the PSUs used in the 198594 National Health Interview Survey (NHIS).2 The hospitals are divided into 16 subsamples;
each subsample has a data collection period of 4 weeks. In year 2010, the most recent year
available, about 112 PSUs, 488 hospitals, 388 EDs, and 100 visits in each ED were sampled. The
validity and quality of this survey and database have been assessed in more than 100 previous
publications.2
Given the sampling method, the results from NHAMCS should be nationally
representative. All of the analyses should be weighted to get national estimates. In order to get
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reliable national estimates, the estimates must be based on at least 30 cases and the estimates
should have a relative standard error of less than 30%.1
Data in NHAMCS are abstracted from patient records by a trained nurse who works in
the hospital. A nurse is chosen because she/he is more acquainted with the hospital’s records,
which makes it easier to abstract the information. A field representative then checks on the
quality of the data collection and is concerned mostly with the completeness of the form.
Incomplete data items are sometimes imputed using a hot deck procedure by assigning a value
from a randomly selected patient record form with similar characteristics. Then, the data is sent
to be coded by a trained medical coding personnel from the Division of Data Processing at the
NCHS computer facility in Research Triangle Park North Carolina.2

Study population
Data for this study were obtained from1992 to 2010. Patients who were included in this
study had to have an admission diagnosis of AMI (ICD-9-CM code 410.xx) and be at least 55
years of age. Admission diagnosis was chosen instead of discharge diagnosis because this study
is interested in the medications given in the ED, which are prescribed based on the patient’s
admission diagnosis. To ensure the accuracy of the admission diagnosis, patients were excluded
if their diagnosis was considered questionable (rule-out). It is important to note here that from
year 1992 to 1996 the variable indicating whether the diagnosis is probable or not was not
available, hence these years had larger numbers of participants; meaning it is probable that some
of these cases did not have a confirmed AMI diagnosis. Another reason for choosing the
admission diagnosis is for consistency purposes; the admission diagnosis was available in all the
years but discharge diagnosis was only available from year 2005 onwards.
44

Study design
This study used a cross-sectional design for all of the aims. The first aim explored the
trend in the utilization of antiplatelet agents and beta-blockers from 1992-2010. The second aim
explored the bivariate associations between receiving antiplatelet agents or beta-blockers and
demographic, clinical, visit, and hospital characteristics. The third aim determined whether an
association existed between receiving antiplatelet agents or beta-blockers and in-hospital
mortality and length of hospital stay. In this aim, only years 2005 onwards were used because
these are the only years that have discharge data. Moreover, only patients who are admitted to
the hospital will be used in this aim, meaning patients who died in the ED or patients who were
transferred to other hospitals will be excluded. The fourth aim evaluated the association between
the use of a computerized guideline reminder in the ED and the ED usage patterns of antiplatelet
agents and beta-blockers.
Data extraction and manipulations
Drug data variables
The drugs of interest in this study are: antiplatelet agents (aspirin, clopidogrel,
ticlopidine, and dipyridamole) and beta-blockers (all beta-blockers available in NHAMCS,
summarized in Table 3.1). These drugs were chosen because they were recommended as part of
acute medical care for an AMI in the ACC/AHA guidelines. In these guidelines, the use of
aspirin and beta-blockers in the first 24 hours is considered a quality indicator. It was also
mentioned in the guidelines that if aspirin was contraindicated, clopidogrel, ticlopidine, or
dipyridamole can be used instead. An important matter to note here is that in 2006, NHAMCS
switched from the Food and Drug Administration’s (FDA) National Drug Code Directory (NDC)
to Lexicon Plus®, a proprietary database of Cerner Multum, Inc., to code characteristics of drugs
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listed on the patient record.3A drug conversion file and a SAS program were supplied by
NHAMCS team in order to recode the years before 2006 to Lexicon Plus® for researchers
interested in merging data before 2006 with year 2006 and after. The drug codes used in this
study are summarized in Table 3.1.
Table 3.1: Drug codes
Drug group
Antiplatelet agents

Beta-blockers

Drug name and codes
Aspirin (d00170)
Clopidogrel (d04258)
Ticlopidine (d00514)
Dipyridamole (d00213)
Metoprolol (d00134)
Atenolol (d00004)
Carvedilol (d03847)
Nadolol (d00018)
Metipranolol (d00297)
Betaxolol (d00176)
Bisoprolol (d00709)

Propranolol (d00032)
Acebutolol (d00128)
Pindolol (d00137)
Timolol (d00139)
Esmolol (d00224)
Carteolol (d00708)

Demographic data variables
Age was a continuous variable that was recoded into a categorical variable. This variable
grouped patients into older or equal to 65 and younger than 65. Sex was coded into males and
females. Ethnicity was originally coded as Hispanic and non-Hispanic. For patient race,
NHAMCS had a recode for all years that defined race as white, black, and other, which was used
for this study. Patient residence was defined as private, nursing home, institutions, and homeless
beginning in 2005; however, the years earlier defined patient residence as nursing home or not
nursing home. For consistency purposes, the nursing home and not nursing home coding was the
one chosen to be used for this study. The source of payment variable was recoded into the
following categories: Medicare, Medicaid, private insurance, and other. The “other” category
included workers compensation, charity, and self-pay.
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Clinical data variables
Systolic blood pressure (SBP) and heart rate (HR) were continuous variables that were
recoded to categorical variables. For the SBP variable, patients who had a SBP that is less than
or equal to 90 mmHg were considered to be hypotensive; more than 90 mmHg was not
hypotensive. For the HR variable, patients who had an HR that is less than or equal to 60 bpm
were considered to be bradycardic; more than 60 bpm was not bradycardic. These variables were
defined this way to identify patients who had a potential contraindication to beta-blockers. The
clinical presentation of interest for these patients is whether or not they had chest pain.
NHAMCS has a variable that specifies the patients’ reason for visit, which coded the patients’
verbatim of why they are visiting the ED. The chest pain code was looked up, and then a variable
specific to chest pain was created.
The triage variable presented some challenges as the coding changed three times across
the study period. A new variable was created to put all these changes into consideration by
grouping triage into two categories: high and low. High triage patients were given a priority to be
seen within 1 hour or less; low triage patients were given a priority to be seen within 1-2 hours.
The number of procedures done and number of diagnostic services done were continuous
variables. Cardiac enzyme test and cardiac monitor test variables were both coded as yes/no
variables, the actual result of the test is not provided.
Visit Data variables
The time variable was recoded to three categories: day, evening, and night. Day was
considered to be 8:00 am to 3:59 pm; evening was considered to be 4:00 pm to 11:59 pm; and
night was considered to be 12:00 am to 7:59 am. The variable representing the day of the week
of the visit was recoded to weekday and weekend. Mode of arrival variable coding changed
47

across the years, some years had more than one transport category and others had only
ambulance or not. Hence, it was recoded into arrival by ambulance or not, for consistency
purposes throughout the years. The provider seen variable was also collected differently across
the years with different variable names, so it was defined into the following categories;
physician, physician assistant, resident physician, nurse practitioner, and nurse (RN/LPN). The
provider seen variable is coded in a way that you can select all that apply. For example, a patient
can be seen by a nurse, a physician, and resident. Patients’ discharge variables were only
available starting year 2005. Discharge status was defined as alive or dead. Length of hospital
stay (LOS) was a continuous variable expressed in days.
Hospital Data Variables
Hospital ownership and Metropolitan Statistical Area (MSA) variables had different
names across the years, so they had to be recoded for consistency purposes. Hospital ownership
had 3 categories: proprietary (for-profit), government (non-federal), and voluntary (not-profit).
MSA was two categories: MSA and non-MSA. Hospital region was expressed as Northeast,
Midwest, South, and West. The computerized guideline reminder variable was only available
starting year 2005 and was a simple yes/no variable, there was no further explanation of that
variable to show its actual content.
Design variables
In order to get national estimates and to account for the four-stage survey sampling
design, design variables provided from NHAMCS must be used in all analyses. The first design
variable is patient weight (PATWT), the second is stratum weight (CSTRATM), and the third is
PSU weight (CPSUM). Years prior to 2002 did not have these design variables; hence,
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NHAMCS has provided a SAS program to add these design variables to those years for
researchers interested in merging data before 2002 with year 2002 and after.
Outcome Variables
For aims 1, 2, and 4, the outcome variables of interest are antiplatelet agent utilization
and beta-blocker utilization. Utilization for each drug class is expressed by yes/no for each visit,
so they it is visit-level data. For aim 3, the outcome variables are in-hospital mortality and length
of hospital stay.
Predictor Variables
Predictors will be grouped into patient demographics (sex, race, ethnicity, residence, and
source of payment), patient clinical characteristics (triage level, SBP, HR, clinical presentation,
number of procedures done in ED, number of diagnostic services done, whether they did a
cardiac enzyme test, and whether they had cardiac monitoring), visit characteristics (time and
day of arrival, provider seen, transport used to get to the hospital), hospital characteristics
(hospital region, hospital ownership, MSA, and availability of computerized guideline
reminders). Predictor variables summary and coding are presented in Table 3.2.

Table 3.2: Predictor Variables
Predictor Variables
Patient Demographics
Sex
Race
Ethnicity
Patient residence
Expected source of payment
Patient Clinical Characteristics
Systolic blood pressure (SBP)
Heart rate (HR)

Coding
Male, Female
White, Black, Other
Hispanic, Not Hispanic
Nursing home, Other
Medicare, Medicaid, Private, Other
Hypotensive “≤ 90mmHg” (Yes/No)
Bradycardic “≤60bpm” (Yes/No)
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Number of procedures done during
the ED visit
Number of diagnostic services
done during the ED visit
Patient clinical presentation
Triage level
Cardiac Enzyme test
Cardiac Monitor test
Visit Characteristics
Time of arrival
Day of Arrival
Mode of transport
Provider seen
Hospital Characteristics
Hospital region
Hospital ownership
Metropolitan Statistical Area
ED Computerized guideline
reminders

Actual number.
Actual number.
Chest pain (Yes/No)
High priority (1-60 min), Low priority (>60
min)
Yes, No
Yes, No
Day (8am-3:39pm), Evening (4pm11:59pm), Night (12am-7:59am)
Weekday, Weekend
Ambulance, Other
Physician, Physician Assistant, Resident,
Nurse Practitioner, Nurse (RN/LPN)
Northeast, Midwest, South, West
Proprietary, Government, Nonprofit
MSA, non-MSA
Yes, No

Patient Demographics
Several studies have shown that patient demographics such as gender and race can be
important predictors of AMI treatment. Females and black patients have been shown to be
undertreated.4-7 Patient’s residence also acts as a predictor of AMI treatment. A recent study
showed that patients admitted from nursing homes were less likely to receive treatment for
AMI.8 Furthermore, the effect of source of payment is also of importance on AMI care. A
nationally representative study has shown that patients with private insurance were more likely
to have appropriate AMI care.9
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Patient Clinical Characteristics
Patient clinical characteristics can be considered important predictors of AMI treatment.
A recent study showed that if a patient with AMI was given a low-priority triage level, it was
associated with delay in treatment, longer hospital stay, and higher mortality.10 A multi-center
study that looked at chest pain in older adults found that it is more difficult to diagnose acute
chest pain in older adults, so this may lead to a lower-priority triage and hence delayed care.11
Visit Characteristics
The timing of the ED visit, both time of day and the day of the week, has been shown to
be an important consideration. A recent study showed that patients admitted off-hours (i.e., 4pm
to 7:30am on weekdays or all day on weekends) were more likely to have in-hospital mortality
and also experience a delay in AMI care.12 From the standpoint of day of arrival, a study showed
that patients admitted during the weekend had higher in-hospital mortality, which may be
explained by the disparities in resources and expertise of healthcare providers working during
weekends when compared to weekdays.13
Hospital Characteristics
Some hospital characteristics like, hospital region and hospital ownership may have an
effect on AMI care. A study found that patients in the northeast region were more likely to get
better quality of AMI care.9 In the same study, it was shown that patients who were in
governmental hospitals were less likely to receive appropriate treatment for AMI.9
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Statistical analysis
Descriptive statistics were used to describe the baseline characteristics for our patients.
Continuous variables were expressed as the weighted mean ± standard deviation (SD) and the
95% confidence intervals (CI) of the mean. The SURVEYMEANS procedure will be used for
continuous variables. Categorical variables were expressed as the weighted frequency and the
row percent and 95% CI of the row percent. The SURVEYFREQ procedure was used for
categorical variables. The a priori significance level is set to two-sided p-value of 0.05. SAS
version 9.3 was used for all analyses.
In this study, the aim was to generate hypotheses, so predictive model building strategies
were not used. Given the exploratory nature of this study, the focus is on adjusting for potential
confounders and providing insight for further studies in this area.
For the first aim, which was to examine the temporal trend in receiving antiplatelet agents
and beta-blockers, the SURVEYLOGISTIC procedure was used to conduct a logistic regression
analysis. Two models will be used, one for antiplatelet agents as the outcome variable, and the
other with beta-blockers as the outcome variable. The predictor variable for both models was
year as a continuous variable, ranging from 1992 to 2010. The odds ratio was used to explain the
magnitude and direction of the trend.
For the second aim, the effect of demographic, clinical, visit, and hospital characteristics
on receiving antiplatelet agents and beta-blockers was examined. A bivariate logistic regression
was carried out using the SURVEYLOGISTIC procedure between the outcome variables, which
was the utilization of antiplatelet agents or beta-blockers, and the predictor variables. The odds
ratio was used to express the magnitude and direction of the relationship. Then, if the
relationship is significant, a multivariate logistic regression will be carried out controlling for
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age, sex, race, and year. These variables were chosen because they have strong evidence
confirming their effect on anti-platelet agent and beta-blocker utilization rates, plus they are
available most of the time for all patients.4-7
For the third aim, the first outcome examined was in-hospital mortality. Given the low
mortality rate, only 15 cases of mortality, it was not possible to carry out a Kaplan-Meir Survival
Analysis nor a logistic regression analysis. Hence, a chi-square test was used to determine
whether the patients who took an antiplatelet agent or beta-blocker were different from the ones
who did not in their rate of in-hospital mortality. The SURVEYFREQ procedure with CHISQ
option was used to carry out the chi-square test. The second part of the third aim is looking at
whether guideline-concordant therapy has an effect on length of hospital stay. Since the
dependent variable in this analysis is continuous, the SURVEYREG procedure was used to carry
out a linear logistic regression between LOS and antiplatelet agents or beta-blockers. The
regression coefficient was used to express the magnitude and direction of the relationship.
For the last aim, the association between the availability of a computerized guideline
reminder in the ED and the ED utilization of antiplatelet agents and beta-blockers was evaluated.
Like the first aim, a bivariate logistic regression was conducted using the SURVEYLOGISTIC
procedure in SAS. The odds ratio was used to express the magnitude and direction of the
relationship. If the relationship is significant, then a multivariate logistic regression was carried
out adjusting for age, sex, race, and race.
All the analyses were weighted to get national estimates. In order to get reliable national
estimates, our estimates must be based on at least 30 cases. The other requirement for reliability
is that estimates should have a relative standard error of less than 30%, was not achievable in this
study. We reached this conclusion after long discussions with NHAMCS statisticians. We
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concluded that our data may be highly clustered because only a very few EDs may account for
most visits for our specific diagnosis, which will mean that our standard errors will always be
high because of that clustering. The SAS code for the data manipulation and data analysis is
provided in Appendix A.
Human subject protection and data privacy
Data files were available from the National Center for Health Statistics, which codes and
encrypts the data to prevent identifiability resulting in a dataset compliant with the Health
Insurance Portability and Accountability Act of 1996. This study qualified for exemption
according to 45 CFR 46.101(b) Category 4 at Virginia Commonwealth University internal
review board (IRB). (VCU IRB#: HM14455). A copy of the IRB Approval form can be found in
Appendix B.

54

References
1. NHAMCS manual. Centers for Disease Control and Prevention Web site.
http://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm. Accessed Oct 23, 2011.
2. McCaig LF, McLemore T. Plan and Operation of the National Hospital Ambulatory Medical
Care Survey. National Center for Health Statistics. Vital and Health Stat 1(34). 1994.
3. 2006 NHAMCS micro-data file documentation. Centers for Disease Control and Prevention
Web site. http://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm. Accessed April 14, 2012.
4. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and
treatment of non–ST-segment elevation acute coronary syndromes: large-scale observations from
the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse
Outcomes With Early Implementation of the American College of Cardiology/American Heart
Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol.
2005;45:832-7.
5. Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management
of unstable angina and non–Q-wave myocardial infarction: the TIMI III registry. JAMA.
1996;275:1104-12.
6. Vaccarino V, Rathore SS, Wenger NK, et al. Sex and racial differences in the management of
acute myocardial infarction, 1994 through 2002. N Engl J Med. 2005;353:671-82.
7. Mehta RH, Marks D, Califf RM, et al. Differences in the clinical features and outcomes in
African Americans and whites with myocardial infarction. Am J Med. 2006;119:70.e1-8.
8. Radcliff T and Levy C. Examining Guideline-concordant care for acute myocardial infarction
(AMI): the case of hospitalized post-acute and long-term care (PAC/LTC) residents. Journal of
hospital medicine. 2010;5:E3-E10.
9. Pham J, Kelen G, Pronovost P. National study on the quality of emergency department care in
the treatment of acute myocardial infarction and pneumonia. Acad Emerg Med. 2007;14:10:85663.
10. Atzema C, Schull M, Austin P, Tu J. Temporal changes in emergency department triage of
patients with acute myocardial infarction and the effect on outcomes. Am Heart J. 2011;162:4519.
11. Solomon CG, Lee TH, Cook EF, et al. Comparison of clinical presentation of acute
myocardial infarction in patients older than 65 years of age to younger patients: the Multicenter
Chest Pain Study experience. Am J Cardiol. 1989; 63(12):772-6.
12. Maier B, Behrens S, Graf-Bothe C, et al. Time of admission, quality of PCI care, and
outcome of patients with ST-elevation myocardial infarction. Clin Res Cardiol. 2010;99:565–
572.

55

13. Bell C, Redelmeier D. Mortality among patients admitted to hospitals on weekends as
compared with weekdays. N Engl J Med. 2001;345:663-8.

56

CHAPTER 4
Results

Descriptive Results
A total of 1771 visits (weighted: 6.1 million visits) were eligible for this study. Almost
3.33 million (54%) [95% CI: 51.7% to 57.1%] of our population were females with a mean age
of 72.1 (±13.7) years. This population is 87% (5.32 million) white [95% CI: 84.9% to 89.1%]
and 94% (5.33 million) non-Hispanic [95% CI: 91.8% to 95.3%]. A summary of patients’
demographics is presented in Table 4.1.
Table 4.1: Patient Demographics
Patients’ Demographics
Total population = 6,118,050
Age
Sex
- Female
- Male
Race
- White
- Black
- Other**
Ethnicity
- Non-Hispanic
- Hispanic
Source of payment***
- Private
- Medicare
- Medicaid
- Other†
Patients’ residence††
- Nursing home
- Other †††

Unweighted
Frequency
---

Weighted Frequency
(%)
72.1 (±13.7)*

95% CI of the
%
[71.4 – 72.7]

951
820

3,329,349 (54.4)
2,788,701 (45.6)

[51.7 – 57.1]
[42.9 – 48.3]

1,519
179
73

5,323,371 (87.0)
589,075 (9.6)
205,604 (3.4)

[84.9 – 89.1]
[7.9 – 11.4]
[2.1 – 4.6]

1,558
105

5,328,722 (93.6)
365,550 (6.4)

[91.8 – 95.3]
[4.7 – 8.2]

251
689
91
94

853,526 (20.2)
2,690,918 (63.7)
327,806 (7.8)
350,091 (8.3)

[16.8 – 23.7]
[59.7 – 67.7]
[5.9 – 9.6]
[6.1 – 10.5]

50
575

168,520 (7.9)
1,971,606 (92.1)

[4.9 – 10.8]
[89.2 – 95.0]

* The numbers represent the mean and the calculated standard deviation.
** The other race category included Asian, Native Hawaiian/other Pacific Islander, American Indian/Alaska Native,
and more than one race reported.*** Sources of payment data started to be collected in year 1995.
† The other source payment category included worker’s compensation, self-pay, and no charge/charity.
†† Patient residence data started to be collected in year 2001.
††† The other residence category included private residence, other institution, other residence, and homeless.
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Patients’ clinical characteristics, diagnostic services, and procedures were available in
NHAMCS database. Patients who had chest pain in this older adult population were 3.7 million,
almost 89% of the population. Patients who had a contraindication to beta-blockers were around
20%: 11% hypotensive, and 15% bradycardic. A summary of patients’ clinical characteristics,
diagnostic services, and procedures is presented in Table 4.2.
Table 4.2: Patient Clinical Characteristics
Clinical Characteristics
Total population = 6,118,050
Chest pain
- Yes
- No
Hypotension*
- Yes
- No
Bradycardia*
- Yes
- No
Triage**
- High (0-60mins)
- Low (>60mins)
Cardiac Enzymes test***
- Yes
- No
Cardiac monitor†
- Yes
- No
Electro-cardio-gram
- Yes
- No
Total procedures done†,††
Total diagnostic services
done †

Unweighted
Frequency

Weighted
Frequency (%)

95% CI of
the %

1,055
123

3,666,299 (88.9)
457,443 (11.1)

[86.4 – 91.4]
[8.6 – 13.6]

70
624

252,549 (10.7)
2,116,200 (89.3)

[7.7 – 13.6]
[86.4 - 92.3]

107
587

354,49 (14.9)
2,014,2527 (85.1)

[11.6 – 18.4]
[81.6 – 88.4]

1,567
83

5,341,873 (94.5)
312,314 (5.5)

[92.9 – 96.0]
[3.9 – 7.1]

252
108

992,945 (68.9)
448,036 (31.1)

791
374

2,996,405 (68.4)
1,382,190 (31.6)

[64.5 – 72.4]
[27.6 – 35.5]

1,582
189
---

5,473,217 (89.5)
644,833 (10.5)
1.16 (±1.65)

[87.4 – 91.5]
[8.5 – 12.6]
[1.1 – 1.2]

---

6.67 (±4.85)

[6.4 – 6.9]

[62.9 – 74.9]
[25.0 – 37.1]

*Data about blood pressure and heart rate were first collected in 2001.
**The high triage category represents urgent and emergent cases, the low triage category represent not urgent cases.
*** Data about cardiac enzyme test was first collected in 2005.
† Data about cardiac monitor, total procedure done, and diagnostic services done was first collected in 1995.
†† The numbers represent the mean and the calculated standard deviation.
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The day and time the patient arrived to the ED, the mode of their arrival, the providers’
seen, the type of ward they were admitted to, number of drugs taken, and their discharge status
were all collected. A majority of patients were admitted on a weekday (almost 70%). Also, a
majority of patients were seen by an attending physician and a nurse (91% and 90%,
respectively). Patients visit characteristics are summarized in Table 4.3.
Table 4.3: Patient visit characteristics
Patients’ Visit Characteristics
Total population = 6,118,050
Time*
- Day (08:00-15:59)
- Evening (16:00-23:59)
- Night (00:00-7:59)
Day
- Weekday
- Weekend
Arrival**
- Ambulance
- Other
Provider seen***
- Attending physician
- Physician assistant
- Resident/intern
- Nurse practitioner
- RN/LPN nurse
Admission ward†
- Critical Care Unit
- OR/Cath lab/SDU
- Other wards
Discharge status††
- Alive
- Dead
Number of drugs†††
- (0-2 drugs)
- (3-5 drugs)
- (6-8 drugs)

Unweighted
Frequency

Weighted Frequency
(%)

95% CI of the
%

501
394
256

1,817,897 (41.9)
1,506,112 (34.8)
1,006,024 (23.2)

[38.2 – 45.8]
[31.6 – 38.0]
[20.0 – 26.5]

807
336

2,858,609 (70.4)
1,199,857 (29.6)

[67.2 – 73.7]
[26.3 – 32.8]

252
238

958,184 (54.8)
791,567 (45.2)

[48.6 – 60.9]
[39.1 – 51.4]

1,622
42
308
23#
1,588

5,570,978 (91.1)
144,812 (2.4)
889,955 (14.5)
66,814 (1.5)
5,515,296 (90.1)

[89.1 – 93.0]
[1.3 – 3.4]
[12.1 – 17.0]
[0.7 – 2.3]
[87.9 – 92.3]

97
62
79

388,635 (40.7)
256,438 (26.7)
309,764 (32.4)

[32.9 -28.5]
[20.0 – 33.7]
[24.1 – 40.8]

222
15#

902,868 (95.6)
41,310 (4.41)

[93.0 – 98.2]
[1.8 – 6.9]

174
208
135

603,248 (32.5)
754,666 (40.7)
498,175 (26.8)

[26.3 – 38.7]
[34.6 – 46.7]
[21.1 – 32.6]

* Data about time of arrival was first collected in 1995. # It was less than 30 row cases, so not reliable estimates
** Data about arrival mode was first collected in 2003.
*** Numbers of providers seen is not mutually exclusive (i.e. a patient can be seen by multiple providers).
† OR = Operation Room, Cath lab = Catheterization lab, SDU = Step Down Unit, Data about admission was first
collected in 2005.
††Data about whether the patient was discharged from any hospital within the last 7 days and data about discharge
status was first collected in 2005. ††† Data about number of drugs from 2003 to 2010
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Hospital characteristics are summarized in Table 4.4. Data specific to the ED structure
(i.e. computerized guideline reminders) were only collected beginning in 2005. Almost 52% of
the EDs had computerized guideline reminders.
Table 4.4: Hospital Characteristics
Hospital Characteristics
Total population = 6,118,050
Region
- Northeast
- Midwest
- South
- West
Metropolitan Statistical Area
- MSA
- Non-MSA
Hospital Ownership
- Voluntary/non-profit
- Government/non-federal
- Proprietary
Guideline reminders*
- Yes
- No

Unweighted
Frequency

Weighted Frequency
(%)

95% CI of the %

525
421
496
329

1,507,271 (24.6)
1,651,986 (27.0)
1,926,372 (31.5)
1,032,421(16.9)

[20.5 – 28.8]
[21.9 – 32.1]
[26.9 – 35.9]
[13.8 – 19.9]

1,455
316

4,615,904 (75.4)
1,502,146 (24.6)

[68.2 – 82.7]
[17.3 – 31.8]

1,405
175
191

4,751,702 (77.7)
657,327 (10.7)
709,021 (11.6)

[74.1 – 81.2]
[8.2 – 13.3]
[8.9 – 14.2]

104
95

435,149 (52.2)
398,398 (47.8)

[42.1 – 62.3]
[37.7 – 57.9]

* Data about computerized guideline reminders was first collected in 2005.

Results by objective
Objective 1: Trend in use of anti-platelet agents and beta-blockers across 1992-2010
Both anti-platelet agents and beta-blockers showed a positive trend across the years (OR
= 1.09 [95% CI: 1.07 to 1.19] and OR = 1.16 [95% CI: 1.13 to 1.19], respectively) as shown in
Figure 4.1. The lowest antiplatelet agent utilization was in 1992 at 13% and highest in 2010 at
almost 59%. For beta-blockers, the lowest was in 1994 at around 2% and the highest in 2007 at
38%. There was a gradual increase in the use of both anti-platelet agents and beta-blockers.
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Trend of Antiplatelet agents and Beta-blockers
across the years 1992-2010
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Figure 4.1: Trend of antiplatelet agents and beta-blockers utilization across the years
Objective 2: Predictors of anti-platelet agents and beta-blocker use
Age was a significant predictor of anti-platelet agents use. Younger adults (i.e., <65 years
old) were more likely to receive an anti-platelet agent than older adults (OR = 1.316 [95% CI:
1.077 to 1.609]); however, age was not found to be a significant predictor of beta-blocker use.
Sex, on the other hand, was considered to be a significant predictor of beta-blocker use. Females
were almost 70% less likely to receive a beta-blocker compared to males (OR = 0.699 [95% CI:
0.471 to 0.950]). Sex was not considered a significant predictor of antiplatelet agents use. Race
and ethnicity were not significant predictors for either antiplatelet agents or beta-blockers.
Patients not living in nursing homes were almost 2.5 times more likely to get antiplatelet agents
(OR = 2.477 [95% CI: 1.254 to 4.894]); however, there was no significant relationship between a
patient’s residence and beta-blocker use. The source of payment was not considered to be a
significant predictor for either antiplatelet agents or beta-blockers use.
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Several patient clinical characteristics were significant predictors of medication use.
Those patients with no chest pain were less likely to get a beta-blocker (OR = 0.330 [95% CI:
0.132 to 0.827]). Patients with high triage were almost 2.5 times more likely to get an antiplatelet
agent (OR = 2.483 [95% CI: 1.284 to 4.801]); however, triage did not have a significant
relationship with beta-blockers use. Interestingly, for every 1 point increase in the number of
diagnostic services the patients received in the ED, the more likely he/she got an antiplatelet
agent (OR= 1.145 [95% CI: 1.089 to 1.205]) or a beta-blocker (OR = 1.074 [95% CI: 1.000 to
1.153]).
Patients who did not arrive in an ambulance were more likely to receive anti-platelet
agents (OR = 1.652 [95% CI: 1.072 to 2.545]); however, arrival by ambulance was not a
significant predictor of beta-blocker utilization. The time and day of arrival were not significant
predictors for either antiplatelet agents or beta-blocker use. Patients who were seen by a nurse
practitioner were 8% less likely to get an antiplatelet agent (OR = 0.082 [95% CI: 0.022 to
0.307]). Patients who were treated in a hospital that is located in a Metropolitan Statistical Area
(MSA) were more likely to get an antiplatelet agent (OR = 1.825 [95% CI: 1.331 to 2.502]). The
summary of all these bivariate associations are presented in Tables 4.5 and 4.6.
After adjusting for demographic characteristics (age, sex, and race) and year, all
significant predictors of the use of antiplatelet agents remained significant, but for beta-blockers
only chest pain remained to be a significant predictor of utilization. Results of the multivariate
analysis are summarized in Tables 4.7 and 4.8. All unadjusted and adjusted analyses are
summarized in Figure 4.2 and 4.3.
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Table 4.5: Bivariate associations between patients’ demographic, clinical, visit, and hospital
characteristics and the use of antiplatelet agents
Predictor variables
Demographic
- Age (younger than 65 vs. 65 and older)
- Sex (females vs. males)
- Race (referent: black)
- Other
- White
- Ethnicity (Hispanic vs. non-Hispanic)
- Payment (referent: Medicaid)
- Other
- Private
- Medicare
- Residence (other residence vs. nursing homes)
Clinical
- Chest pain (no chest pain vs. chest pain)
- Triage (high vs. low)
- Total diagnostic services
Visit
- Time (referent: night)
- Day
- Evening
- Day (weekend vs. weekday)
- Arrival (other transport vs. ambulance)
- Provider seen
- Physician (no vs. yes)
- Resident (no vs. yes)
- Nurse RN/LPN (no vs. yes)
- Physician assistant (no vs. yes)
Hospital
- Region (referent: West)
- Northeast
- Midwest
- South
- MSA (MSA vs. non-MSA)
- Ownership (referent: Proprietary)
- Voluntary/non-profit
- Government/non-federal
*p<0.05
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Odds ratio (OR)

95% CI of OR

*1.316
0.815

[1.077 - 1.609]
[0.649 – 1.024]

0.881
0.692
1.184

[0.434 – 1.786]
[0.461 – 1.038]
[0.712 – 1.970]

1.732
1.364
0.934
*2.477

[0.855 – 3.508]
[0.767 – 2.424]
[0.542 – 1.611]
[1.254 – 4.894]

0.792
*2.483
*1.145

[0.490 – 1.280]
[1.284 – 4.801]
[1.089 – 1.205]

0.897
0.943
1.061
*1.652

[0.596 – 1.350]
[0.628 – 1.413]
[0.768 – 1.466]
[1.072 – 2.545]

0.733
0.745
0.693
1.037

[0.465 – 1.155]
[0.507 – 1.093]
[0.447 – 1.077]
[0.412 – 2.606]

0.842
0.747
0.807
*1.825

[0.594 – 1.192]
[0.538 – 1.038]
[0.569 – 1.144]
[1.331 – 2.502]

1.152
1.016

[0.784 – 1.695]
[0.565 – 1.827]

Table 4.6: Bivariate associations between patients’ demographic, clinical, visit, and hospital
characteristics and use of beta-blockers
Predictor variables
Demographic
- Age (younger than 65 vs. 65 and older)
- Sex (females vs. males)
- Race (referent: black)
- Other
- White
- Ethnicity (Hispanic vs. non-Hispanic)
- Payment (referent: Medicaid)
- Other
- Private
- Medicare
- Residence (other residence vs. nursing homes)
Clinical
- Chest pain (no chest pain vs. chest pain)
- Triage (high vs. low)
- Total diagnostic services
Visit
- Time (referent: night)
- Day
- Evening
- Day (weekend vs. weekday)
- Arrival (other transport vs. ambulance)
- Provider seen
- Physician (no vs. yes)
- Resident (no vs. yes)
- Nurse RN/LPN (no vs. yes)
- Physician assistant (no vs. yes)
Hospital
- Region (referent: West)
- Northeast
- Midwest
- South
- MSA (MSA vs. non-MSA)
- Ownership (referent: Proprietary)
- Voluntary/non-profit
- Government/non-federal
* p<0.05
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Odds ratio (OR)

95% CI of OR

1.221
*0.669

[0.892 – 1.670]
[0.471 – 0.950]

1.269
0.863
1.870

[0.462 – 3.483]
[0.517 – 1.442]
[0.992 – 3.524]

0.993
1.817
1.344
1.798

[0.392 – 2.520]
[0.877 – 3.765]
[0.702 – 2.575]
[0.621 – 5.203]

*0.330
1.604
*1.074

[0.132 – 0.827]
[0.656 – 3.922]
[1.000 – 1.153]

0.860
1.128
1.164
1.384

[0.520 – 1.424]
[0.685 – 1.859]
[0.803 – 1.686]
[0.850 – 2.254]

1.030
1.014
1.723
1.293

[0.560 – 1.894]
[0.612 – 1.682]
[0.993 – 2.988]
[0.457 – 3.653]

1.248
0.675
0.866
1.555

[0.723 – 2.156]
[0.361 – 1.263]
[0.492 – 1.524]
[0.874 – 2.767]

*2.263
2.148

[1.129 – 4.534]
[0.945 – 4.882]

Table 4.7: Multivariate analysis of predictors of antiplatelet agent use*
Predictor Variables
Age (younger than 65 vs. 65 and older)
Residence (other residence vs. nursing homes)
Triage (high vs. low)
Total diagnostic services
Arrival (other transport vs. ambulance)
MSA (MSA vs. non-MSA)

Odds Ratio (OR)
1.261
2.231
2.833
1.136
1.618
1.692

95% CI of OR
[1.012 – 1.572]
[1.017 – 4.892]
[1.329 – 6.038]
[1.078 – 1.196]
[1.018 – 2.571]
[1.205 – 2.375]

*adjusted for age, sex, race, and year

Table 4.8: Multivariate analysis of predictors of beta-blocker use*
Predictor Variables
Sex (females vs. males)
Chest pain (no chest pain vs. chest pain)
Total diagnostic services

Odds Ratio (OR)
0.725
0.339
1.014

*adjusted for age, sex, race, and year
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95% CI of OR
[0.504 – 1.042]
[0.131 – 0.880]
[0.974 – 1.085]

MSA (MSA vs. non-MSA)
"Adjusted"

Arrival (other transport vs.
ambulance) "Adjusted"
Total diagnostic services
"Adjusted"
Triage (high vs. low)
"Adjusted"
Residence (other residence vs.
nursing homes) "Adjusted"
Age (younger than 65 vs. 65
and older) "Adjusted"

Ownership (Government
vs. Proprietary)
Ownership (Voluntary vs.
Proprietary)
MSA (MSA vs. non-MSA)
Region (South vs. West)

Region (Midwest vs. West)
Region (Northeast vs.
West)
Physician assistant (no vs.
yes)
Nurse practitioner (no vs.
yes)
Nurse RN/LPN (no vs. yes)
Resident (no vs. yes)
Physician (no vs. yes)
Arrival (other transport vs.
ambulance)
Day (weekend vs.
weekday)
Time (Evening vs. night)
Time (Day vs. night)
Total diagnostic services
Triage (high vs. low)
Chest pain (no chest pain
Residence (other vs. chest pain)
residence vs. nursing
homes)
Payment (Other vs.
Medicaid)
Payment (Private vs.
Medicaid)
Payment (Medicare vs.
Medicaid)
Ethnicity (Hispanic vs. nonHispanic)
Age (Younger vs. older
adults)
Race (White vs. black)
Race (Other vs. black)
Sex (Females vs. males)

0

0.5

1

1.5

2

2.5

Less likely to receive anti-platelets

3

3.5

4

4.5

5

5.5

More likely to receive anti-platelets

Figure 4.2: Forest plot of bivariate associations between predictors and anti-platelets use
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Adjusted

Unadjusted

Total diagnostic services
"Adjusted"
Chest pain (no chest pain
vs. chest pain) "Adjusted"
Sex (females vs. males)
"Adjusted"
Ownership (Government
vs. Proprietary)
Ownership (Voluntary vs.
Proprietary)
MSA (MSA vs. non-MSA)
Region (South vs. West)
Region (Midwest vs. West)
Region (Northeast vs.
West)
Physician assistant (no vs.
yes)
Nurse practitioner (no vs.
yes)
Nurse RN/LPN (no vs. yes)
Resident (no vs. yes)
Physician (no vs. yes)
Arrival (other transport vs.
ambulance)
Day (weekend vs.
weekday)
Time (Evening vs. night)
Time (Day vs. night)
Total diagnostic services
Triage (high vs. low)
Chest pain (no chest pain
vs. chest pain)
Residence (other
residence vs. nursing
homes)
Payment (Other vs.
Medicaid)
Payment (Private vs.
Medicaid)
Payment (Medicare vs.
Medicaid)
Ethnicity (Hispanic vs. nonHispanic)
Age (Younger vs. older
adults)
Race (White vs. black)
Race (Other vs. black)
Sex (Females vs. males)

0

0.5

1

1.5

2

2.5

Less likely to receive beta-blockers

3

3.5

4

4.5

5

5.5

More likely to receive beta-blockers

Figure 4.3: Forest plot of bivariate associations between predictors of beta-blocker use
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Objective 3: The effect of the use of anti-platelet agents and beta-blockers on in-hospital
mortality and length of hospital stay
In-hospital mortality in this population was around 4%. After a chi-square test between
the utilization of antiplatelet agents and beta-blockers and in-hospital mortality, there was no
significant difference between patients receiving anti-platelet agents and patients who did not in
their in-hospital mortality (χ2 = 0.008, p= 0.909). However, there was a significant difference
between patients receiving beta-blockers and patients who did not in their in-hospital mortality
(χ2 = 2.518, p= 0.041).
The mean length of hospital stay was 6.6 (±8.2) days. A linear regression between the
utilization of antiplatelet agents and beta-blockers and length of hospital stay indicated that there
was no statistically significant relationship between antiplatelet agents and beta-blockers use and
length of hospital stay (β = 0.937, p = 0.411) and (β = -0.045, p = 0.967) respectively.

Objective 4: The effect of ED guideline reminders on the use of anti-platelet agents and betablockers
Almost 52% hospitals had computerized guideline reminders. A bivariate logistic
regression showed that patients who were treated in EDs that had a computerized guideline
reminder were twice as likely to get an antiplatelet agent (OR = 2.004 [95% CI: 1.052 to 3.815]).
Computerized reminders were not significantly associated with beta-blocker use (OR = 0.594
[95% CI: 0.304 to 1.162]).
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CHAPTER 5
Discussion

Discussion of descriptive results
The representation of females in our study is highly consistent with the literature.1,2 We
found that the older the age group the higher percentage of females (χ2= 104.5, p < 0.001). It has
been suggested that women present with AMI at older ages.1 The percentage of patients who
were admitted from a nursing home in our population was around 7.9%, which is similar to the
proportion of nursing home residents in other studies (6.4%).3
Chest pain is the hallmark symptom of AMI. In our study almost 89% of our patients
experienced chest pain. This was consistent with the older adult literature.1,2 However, when
dividing older adults into different age groups, we found that the older the age group, the less
likely they were to experience chest pain (younger adults (55-64 years) was 90% and older old
adults (≥85 years) was 78%, χ2 = 15.54, p = 0.045). This was also found in other studies that
looked at the differences by age in AMI presentation.2,4
Less than 20% of our patients had a contraindication to beta-blockers. Approximately
11% had bradycardia and almost 15% had hypotension, some patients had both hypotension and
bradycardia. These percentages were similar to a study that looked at the percentage of patients
who had a contraindication to beta-blockers.5
In our study, about 70% of the patients visited the ED during the day or evening shift.
This is consistent with other studies where the percentage of patients who arrived during the day
and evening shift was 69-74% and during the night shift was 26-32%.1,6 Almost half of our
patients arrived by an ambulance, which is also similar to the previous study (45%).1
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Discussion of results by objective
Objective 1: Trend in use of anti-platelet agents and beta-blockers across 1992-2010
This study showed a positive trend in both antiplatelet agents and beta-blockers use. This
also was seen in another study.7 One study found that administration of aspirin and beta-blockers
within the first 24 hours of admission showed a positive trend from years 1990 to 2006.7 Another
study that looked at in-hospital use of aspirin and beta-blockers from years 1992 to 2002 also
found a significant positive increase in both treatments over time.8
In our study, underuse of both antiplatelet agents and beta-blockers in the ED is evident.
Our utilization percentages are hard to compare with other studies in the literature, because most
of the studies reported in-patient utilization rates.2,9,10 Interestingly, even among the studies that
intended to look only at ED care, their definition of acute care was the receipt of medication
within the first 24 hours of admission, which actually may have been in the ED or in the inpatient setting.1,4
This study showed that beta-blockers were highly underused in the ED (overall use =
14%). This underuse may be attributed to the fact that beta-blockers are more often administered
once the patient is admitted to the hospital. Because beta-blockers have a long list of
contraindications that the physician has to check before administration, early use may be hard to
accomplish given the time constraints in the ED.5 Furthermore, whether some of these are
absolute or relative contraindications may be unclear to the physicians, such as non-acute
asthma, COPD, and chronic heart failure.5
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The strong drop in beta-blockers use noticed in our study, from 32% in 2009 to 10% in
2010, may be explained by the 2008 changes in ACC/AHA performance measures that omitted
the recommendation of administering beta-blockers at arrival.11 This change was likely a result
of findings from the COMMIT trial, which found that intravenous beta-blockers administered at
arrival may cause cardiogenic shock for patients with history of heart failure.12 The ACC/AHA
guidelines still consider beta-blockers to be class I indication for many patients.11 Oral betablockers are still useful and effective for a wide range of patients,13 but it was omitted from the
AMI performance measures because of safety concerns.11 This change was widely adopted by
hospitals because this measure was also removed from the AMI measures list common to the
Centers for Medicare & Medicaid Services (CMS) and The Joint Commission in March 2009.14
This wide adoption may be explained by the fact that, If a hospital does not comply to
JCAHO/CMS, it will lose 2.0 percent of their annual market basket update, only hospitals who
are enrolled in the inpatient prospective payment system (IPPS).14
Objective 2: Predictors of anti-platelet agents and beta-blocker use
Age
There is overwhelming evidence for the underuse of effective AMI treatments in the
older adult population.4,7 Our study supported these previous findings since we found older
adults were less likely to receive an antiplatelet agent; however, no significant relationship was
found with beta-blockers. The older adult population is known to have more contraindications to
medications than their counterparts due to their increased comorbidities. For example,
gastrointestinal bleeding is a common problem in older adults that may prevent the
administration of an antiplatelet agent. A previous study found a 15% reduction in the likelihood
of getting aspirin and 21% with beta-blockers, respectively for every 10-year increase in age.4
71

The TIMI III Registry study found that older adults were less likely to receive aspirin and betablockers (p = 0.04).15 This was also confirmed by GRACE global registry, which found that the
older the age group the less likely was the utilization of aspirin and beta-blockers.10 Another
study found that one of the strongest determinants against receiving a beta-blocker was age older
than 65 years.16 Moreover, a study using NRMI database found that older adults (>75) were
consistently less likely to receive beta-blockers within 24 hours of admission across the years
1990 to 2006.7
Sex
There is contradicting evidence about the effect of patient’s sex on the receipt of AMI
treatment. Our study found that females were less likely to receive a beta-blocker in the bivariate
logistic regression analysis; however, after adjusting for age, sex, race, and year, the relationship
did not remain significant, also there was no significant relationship with antiplatelet agents. One
study found that the relationship between sex and AMI treatment was not significant after
adjusting for age.1 They suggested that women were less likely to receive AMI treatment just
because they were generally older at presentation with AMI.1 Several other studies found that
women were consistently older than men when presenting with AMI, and they presented with
atypical symptoms of AMI, like no chest pain, that may also explain the lower use of evidenced
based drugs in females.1,17-23 Four studies using the largest databases of AMI (NRMI,
CRUSADE, TIMI, and CCP) found that women were less likely to receive aspirin and betablockers.7,23-25 Another study found that one of the strongest determinants against receiving a
beta-blocker is female gender.16 Furthermore, a study using the NRMI database found that
females were consistently less likely to receive beta-blockers within 24 hours of admission
across the years 1990 to 2006.7
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Race and ethnicity
In our study we found that race and ethnicity were not associated with receipt of both
antiplatelet agents and beta-blockers. This was consistent with other studies that also found no
significant relationships between race and ethnicity and AMI treatment.26-28 However, in the
TIMI registry, they found that blacks were less likely to get beta-blockers, but there was no
significant relationship with aspirin.15 In a Medicare study, they found that white people are more
likely to get early beta-blockers (OR, 1.14; 95% CI, 1.04 to 1.23).13 Interestingly, a study using
the NRMI database found that blacks were less likely to receive beta-blockers within 24 hours of
admission in the earlier years of the study (1994-1996) but in the later years (2003-2006) they
were more likely to get beta-blockers.7
Payment
There was no significant relationship between the source of payment and receipt of
antiplatelet agents and beta-blockers. This result was expected because more than 60% of our
patients were covered by Medicare, so it is hard to find the effect of payment in this kind of
distribution. Plus, there could be a spill-over effect from the Medicare patients on the other
patients especially that Medicare emphasizes a lot on quality. A previous study looked at the
relationship between source of payment and AMI care, but it only looked at private payment by
differentiating between patients who had an HMO plan and FFS plan. The authors found that
patients with HMO plans were more likely to receive aspirin and beta-blockers comparing to
patients with FFS plan.29
Residence
In our study, patients admitted from nursing homes were less likely to be administered an
antiplatelet agent. This may be attributed to the possibility that nursing home residents may be
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given aspirin by the nursing home staff when AMI is expected (i.e. experiencing chest pain).
This was confirmed by another study, which found that getting aspirin and being admitted from a
nursing home is negatively correlated (Rho = -0.069 (p < 0.001)).3
Chest pain
In our study, patients who did not have chest pain were less likely to receive betablockers, but there was no significant association between antiplatelet agents and chest pain. This
is similar to another study which found that people who experienced chest pain within < 48 hours
of admission were more likely to get beta-blockers (OR, 1.71; 95% CI, 1.58 to 1.84).13 Another
study found that patients who experienced chest pain are more likely to get aspirin.25
Hospital Region, Ownership, and MSA
Our study found no significant relationship between hospital region and receipt of
antiplatelet agents or beta-blockers. Some previous studies have found that hospitals in the
Northeast region did better on various AMI performance measures.6,30
Objective 3: The effect of the use of anti-platelet agents and beta-blockers on in-hospital
mortality and length of hospital stay
In-hospital mortality
Our study found that there was a significant difference in the in-hospital mortality rate
between patients who received beta-blockers and patients who did not. The majority of patients
who took a beta-blocker lived (99%). However, there was no significant difference in the inhospital mortality rate between patients who received an antiplatelet agent and patients who did
not. At 4%, in-hospital mortality in our population was very similar to other studies that looked
at AMI in-hospital mortality (4-7%).16,31-35 The 4% in our study only represents 15 actual cases
of AMI mortality, hence it is not necessarily comparable to the 4% in other studies. We also
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noticed that older age groups in our population had higher in-hospital mortality than the younger
age groups, but it was not significantly different. Other studies found this relationship to be
significant, the older the age group the higher the in-hospital mortality rate.10,32-34 Similar to our
findings, three studies found that beta-blockers were associated significantly with lower inhospital mortality rates.16,31,35 Another study found that the early use of guideline-recommended
therapies (aspirin, beta-blockers, glycoprotein IIb/IIIa inhibitors, heparin, and catheterization)
were associated with lower in-hospital mortality rates.34
Length of hospital stay
Mean LOS was 6.6 (±8.2) days. It was similar to other studies who had hospitalized older
adults with AMI.36 We did not find a significant relationship between receipt of antiplatelet
agents or beta-blockers and length of hospital stay. It may be expected that medical treatment
(i.e. antiplatelet agents and beta-blockers) may not have a significant effect on LOS like
interventional treatments may have (e.g. PCI, CABG, and fibrinolysis). Krumholz et al. found
that patients who received aspirin had a shorter LOS than patients who did not; however, it was
not mentioned if they were significantly different or not.25
Objective 4: The effect of ED guideline reminders on the use of anti-platelet agents and betablockers
Almost 52% of hospitals had computerized guideline reminders. A bivariate logistic
regression showed that patients who were treated in EDs that had a computerized guideline
reminder were twice as likely to get an antiplatelet agent, but it was not significantly associated
with beta-blockers use. As mentioned before, beta-blockers are harder to administer in an ED
setting, so it is not expected that ED reminders may increase their use in the ED. Plus, aspirin
could be prescribed by a nurse or a physician in the ED, unlike beta-blockers which are only
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prescribed by a physician. We cannot compare our results to other studies, since no studies to our
knowledge examined the effect of computerized clinical decision support (CCDS) systems in the
ED on AMI treatment. However, several studies have looked at the effect of CCDS in other
disease states and in different settings.37-40 Few studies have examined the effect of CCDS
system in the ED.41-42 One study used the CCDS system in the ED to screen for HIV. They
found that using the CCDS for this purpose increased the detection rate of HIV and hence helped
in treating undetected HIV cases.41 The other study found that when incorporating pneumococcal
vaccination reminders in the CCDS system in the ED, it helped to overcome existing barriers that
the health professionals had towards pneumococcal vaccination.42
Limitations
The lack of detailed clinical information in the database prevents us from excluding
ineligible subjects for drug therapy, which is especially important for beta-blockers. Only blood
pressure and heart rate were available for us to identify patients who were hypotensive or
bradycardic, which is considered a contraindication to beta-blockers administration. Also,
because of the lack of data on out-of-hospital management, we were unable to determine if
patients received therapy before hospital arrival. This is more relevant with respect to aspirin, as
it may be given in the ambulance or taken at home by the patient. Both of these
misclassifications may have overestimated the percentage of underuse in our study.
If the database shows that a patient was prescribed a drug that does not necessarily mean
that the patient has actually taken the drug. Even when a drug is mentioned to be given in the
emergency department, it does not necessarily mean that the patient was administered the drug.
In our case, there is little that we can do to overcome that, because there is no other way that we
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could find this information other than the emergency department form. We can only
acknowledge this as a limitation, which is common in most database research.
A researcher is limited by the information collected. It is important to have in mind that
the database is not specifically built to answer the research question. Hence, not all the
information needed to carry out the research maybe available. Sometimes the incompleteness of
data would be a minor issue that can be acknowledged, but sometimes it is a major issue that
may cause us to reconsider using this data source. For example, we are limited by the number of
drugs available in each visit record in NHAMCS. From 2003 to 2010, there are 8 drugs
available, from 1995 to 2002, there are 6 drugs available, and from 1992 to 1994, there are 5
drugs available. This may cause us to miss some of the utilization of anti-platelet agents and
beta-blockers, especially in patients with a lot of comorbidities, which may likely receive a large
number of drugs. Another important matter to note here that from year 1992 to 1996 the variable
indicating whether the diagnosis is probable or not was not available. These years had larger
numbers of participants, meaning it is probable that some of these cases did not have a confirmed
AMI diagnosis. We chose to add these years because of our need to meet sample size
requirements for national estimates and acknowledge it as a limitation.
In our study, there was some important information that was not available in order to
describe the population better. For example, the patient’s medical history was not available. If a
patient had a previous AMI in a different setting, which is considered a cardiac risk factor, we
were unable to account for it. Also, a patient’s drug history is not available, so previous usage of
anti-platelets or beta-blockers will not be known. This is important because it could affect the ED
use for these drugs. Furthermore, the patient’s social history, such as smoking status, is not
available, which is also considered to be a cardiac risk factor. Furthermore, sociodemographic
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patient factors are not available such as education, income, primary language spoken, and
employment. Having this information better describes our population, and their risks to
outcomes.
Data may be subject to many types of inaccuracies. There could be miscoding practices,
either deliberately or just by human error. In our database it is more likely to be human error than
deliberate miscoding. Since NHAMCS does not represent administrative claims data and there is
no incentive to deliberately miscode the diagnosis or procedures to get higher reimbursements,
this would be highly unlikely. Diagnosis codes are the only way to identify our population, to
confirm our diagnosis; only visits with unquestionable diagnosis were used. Some studies can
confirm the diagnosis by available clinical information, but in our case it was not possible.
Some limitations arise from our relatively small sample size. We were not able to control
for all available covariates in our multivariate regression analysis. Hence, we only controlled for
important demographic variables, such as age, sex, and race. We were also not able to carry out a
Kaplan-Meir survival analysis to examine in-hospital mortality or a logistic regression analysis,
because we only had 15 cases of mortality across 2005-2010.

Practical implications
Delivering time-sensitive therapies in the ED should be a priority by the hospital staff;
this may be facilitated by forming a system that ensures receipt of these therapies before the
patient is discharged from the ED.43 Having ED clinical pathways and protocols that promote use
of guideline-recommended therapies in the ED is a good approach to ensuring receipt of
antiplatelet agents. These clinical pathways and protocols may be incorporated in a CCDS to
increase their efficiency. Also, it is important to maximize the provision of these effective
medications to AMI patients, irrespective of age and sex.1 When emergency physicians work
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together with other health care providers (e.g., cardiologists and EMS) this will facilitate a better
provision of care in the ED to AMI patients.6 Also, this is an area where ED pharmacists could
best help in, improving the provision of guideline-concordant treatment to older AMI patients
presenting to the ED. A recent literature review have shown that pharmacists have a great role in
the ED in increasing medication safety and improving patient drug reconciliation.44
Future Directions
Research about the care given in the ED setting needs more attention. It is important to
look at other guideline-recommended therapies that should be given in the ED, like fibrinolysis
and PCI in the older adult population. Conducting a study to be at the ED-level could give
another perspective on ED care. Another acute care setting that needs attention is the EMS. More
studies are needed to quantify the actual use of aspirin in EMS, plus other care guidelines like,
12-led-ECG and fibrinolysis in the ambulance. Furthermore, clinical guidelines should create
and validate performance measures that are ED-specific and that merit more research.37 Also,
there are other structure components that are not collected in NHAMCS that may be looked at in
future research, like the effect of being treated with a cardiologist in the ED.
Conclusion
This is the first study to capture this long period of time of ED AMI care for older adults.
It provided national estimates about older adults ED use of antiplatelet agents and beta-blockers
from 1992 to 2010, which showed that both had a positive trend in utilization across the years.
This study confirms the finding that older adults and females have lower utilization rates of AMI
treatment than their counterparts. This study also reveals new relevant associations, like the
effect of chest pain and triage on utilization rates of antiplatelet agents and beta-blockers. This
study attempted to evaluate the impact of having a computerized reminder to prompt ED staff to
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use guidelines, on the usage of antiplatelet agent therapy in the ED. Our results showed that
having a computerized guideline reminder increase the utilization of antiplatelet agents but not
beta-blockers. This study also attempted to see the effect of ED utilization of antiplatelet agents
and beta-blockers on hospital outcomes, like in-hospital mortality and LOS. We only found that
beta-blockers were significantly associated with lower in-hospital mortality. Finally, this study
may help in increasing the awareness of the ED health care professionals of older adults AMI
care.
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APPENDIX A
SAS code

SAS code of data manipulation (example of year 2010)
/*work program for year 2010*/
data nhamcs.nhamcs10work;
set nhamcs.nhamcs10;
if substr(DIAG1,1,3) = '410' then AMI1adm = 1;
else AMI1adm = 0;
if substr(DIAG2,1,3) = '410' then AMI2adm = 1;
else AMI2adm = 0;
if substr(DIAG3,1,3) = '410' then AMI3adm = 1;
else AMI3adm = 0;
if AMI1adm = 1 and prdiag1 = 0 then participant1 = 1;
else participant1 = 0;
if AMI2adm = 1 and prdiag2 = 0 then participant2 = 1;
else participant2 = 0;
if AMI3adm = 1 and prdiag3 = 0 then participant3 = 1;
else participant3 = 0;
if seen72 = 1 then seen = 1;
else seen = 0;
if AGE>=55 then older =1;
else older=0;
if (participant1 = 1 or participant2 = 1 or participant3= 1) and older = 1
and seen= 0 then participant = 1;
else participant= 0;
if
if
if
if

age
age
age
age

>=55
>=65
>=75
>=85

then
then
then
then

agecat
agecat
agecat
agecat

=
=
=
=

3;
2;
1;
0;

if substr(HDDIAG,1,3) = '410' then AMIdisch = 1;
else AMIdisch = 0;
antiplatelet = 0;
if drugid1 = '' and drugid2 = '' and drugid3 = '' and drugid4 ='' and drugid5
='' and drugid6 ='' and drugid7 = '' and drugid8 = '' then antiplatelet = .;
if drugid1 = 'd04258' or 'd00514' or 'd00213' or drugid2 = 'd04258' or
'd00514' or 'd00213' or drugid3 = 'd04258' or 'd00514' or 'd00213' or drugid4
= 'd04258' or 'd00514' or 'd00213' or drugid5 = 'd04258' or 'd00514' or
'd00213' or drugid6 = 'd04258' or 'd00514' or 'd00213' or drugid7 = 'd04258'
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or 'd00514' or 'd00213' or drugid8 = 'd04258' or 'd00514' or 'd00213' then
antiplatelet= 1;
aspirin = 0;
if drugid1 = '' and drugid2 = '' and drugid3 = '' and drugid4 ='' and drugid5
='' and drugid6 ='' and drugid7 = '' and drugid8 = '' then aspirin = .;
if drugid1 = 'd00170' or drugid2 = 'd00170' or drugid3 = 'd00170' or drugid4
= 'd00170' or drugid5 = 'd00170' or drugid6 = 'd00170' or drugid7 = 'd00170'
or drugid8 = 'd00170' then aspirin= 1;
betablocker = 0;
if drugid1 = '' and drugid2 = '' and drugid3 = '' and drugid4 ='' and drugid5
='' and drugid6 ='' and drugid7 = '' and drugid8 = '' then betablocker = .;
if drugid1 = 'd00134' or 'd00004' or 'd03847' or 'd00709' or 'd00128' or
'd00018' or 'd00176' or 'd05265' or 'd00032' or drugid2 = 'd00134' or
'd00004' or 'd03847' or 'd00709' or 'd00128' or 'd00018' or 'd00176' or
'd05265' or 'd00032' or drugid3 = 'd00134' or 'd00004' or 'd03847' or
'd00709' or 'd00128' or 'd00018' or 'd00176' or 'd05265' or 'd00032' or
drugid4 = 'd00134' or 'd00004' or 'd03847' or 'd00709' or 'd00128' or
'd00018' or 'd00176' or 'd05265' or 'd00032' or drugid5 = 'd00134' or
'd00004' or 'd03847' or 'd00709' or 'd00128' or 'd00018' or 'd00176' or
'd05265' or 'd00032' or drugid6 = 'd00134' or 'd00004' or 'd03847' or
'd00709' or 'd00128' or 'd00018' or 'd00176' or 'd05265' or 'd00032' or
drugid7 = 'd00134' or 'd00004' or 'd03847' or 'd00709' or 'd00128' or
'd00018' or 'd00176' or 'd05265' or 'd00032' or drugid8 = 'd00134' or
'd00004' or 'd03847' or 'd00709' or 'd00128' or 'd00018' or 'd00176' or
'd05265' or 'd00032' then betablocker= 1;
if vdayr = 1 or vdayr = 7 then day = 0;
if vdayr >=2 & vdayr <7 then day = 1;
/*change in arrtime unknown coding for 2009*/
if arrtime >=0000 then hours= 0;
if arrtime >=0800 then hours = 1;
if arrtime >=2201 then hours = 0;
if arrtime = (-9) then hours =.;
/*change in rfv unknown
chestpain = 0;
if (rfv1 >=89900 & rfv1
>=89900 & rfv3 <=90000)
chestpain =.;
if rfv1 = 10501 or rfv2
/*change in
if residnce
if residnce
if residnce
/*change
if racer
if racer
if racer

coding for 2009*/
<=90000) or (rfv2 >=89900 & rfv2 <=90000) or (rfv3
or rfv1 = (-9) or rfv2 = (-9) or rfv3 = (-9) then
= 10501 or rfv3 = 10501 then chestpain = 1;

residnce coding for 2009*/
= 2 then ptresidnce = 1;
= 1 or (residnce >=3 & residnce <=5) then ptresidnce = 0;
= (-8) or residnce = (-9) then ptresidnce = .;

in ptrace coding for 2009*/
= 1 then ptrace = 1;
= 2 then ptrace = 2;
= 3 then ptrace = 0;

/*change in paytype unknown coding for 2009*/
if paytyper = 1 then payment = 1;
if paytyper = 2 then payment = 2;
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if paytyper = 3 then payment = 3;
if paytyper >=4 & paytyper <=7 then payment = 0;
if paytyper = (-8) or paytyper = (-9) then payment = .;
/*change arrival coding in 2009*/
if arrems = 1 then arrival = 1;
if arrems = 2 then arrival = 0;
if arrems = (-8) or arrems = (-9) then arrival = .;
/*change
if admit
if admit
if admit
if admit

in admission coding in 2009*/
= 1 then admission = 1;
= 2 or admit = 3 or admit = 4 then admission = 2;
= 5 or admit = 6 then admission = 0;
= (-7) or admit = (-8) or admit = (-9) then admission = .;

/*change in
if immedr =
if immedr =
if immedr =

triage coding
1 or immedr =
4 or immedr =
7 then triage

for 2009*/
2 or immedr = 3 then triage = 1;
5 then triage = 2;
= .;

if dieded = 1 then deathed = 1;
if dieded = 0 then deathed = 0;
if tranoth = 1 then transferhospital = 1;
if tranoth = 0 then transferhospital = 0;
if ethun = 1 then ethnicity = 1;
if ethun = 2 then ethnicity = 2;
if ethun = (-9) then ethnicity = .;
if pulse =<60 then bradycardia = 1;
else bradycardia = 0;
if bpsys =<90 then hypotension = 1;
else hypotension = 0;
if bradycardia = 1 or hypotension = 1 then Contraindication = 1;
else Contraindication = 0;
if attphys = 0 then physcian = 0;
if attphys = 1 then physcian = 1;
if rnlpn = 0 then nurse = 0;
if rnlpn = 1 then nurse = 1;
if msa = 1 then metro = 1;
if msa = 2 then metro = 2;
if owner = 1 then ownership = 1;
if owner = 2 then ownership = 2;
if owner = 3 then ownership = 3;
if
if
if
if

arrtime
arrtime
arrtime
arrtime

>=0800
>=1600
>=0000
= (-9)

& arrtime
& arrtime
& arrtime
then time

=< 1559 then time= 1;
=< 2359 then time = 2;
=< 0759 then time = 3;
= .;

options nofmterr;
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run;
/*check the keep list for every year*/
data nhamcs.nhamcs10small;
set nhamcs.nhamcs10work;
keep betablocker aspirin antiplatelet drugid1 drugid2 drugid3 drugid4 drugid5
drugid6 drugid7 drugid8 seen AMIdisch older participant participant1
participant2 participant3 agecat chestpain day time ptresidnce ptrace arrival
admission payment triage waittime physcian resint nursepr nurse physasst
deathed transferhospital ethnicity age sex pulse bradycardia bpsys
hypotension contraindication disch7da cardenz cardmon ekg totdiag totproc los
hdstat patwt region metro ownership hospcode patcode cstratm cpsum year edwt
ereminde;
run;

SAS code for the analysis program
/*Analysis program for Maryam Alowayesh Dissertation, last modified April 8th
2013*/
/*Demographic Descriptives*/
/*Descriptive age*/
proc surveymeans data=nhamcs.nhamcs10ed_opdappend_end;
var age;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'descriptive age';
options nofmterr;
run;
/*Descriptive demographic: sex race ethnicity payment residence*/
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end;
tables participant*sex participant*ptrace participant*ethnicity
participant*payment participant*ptresidnce/ row CL CLWT;
cluster cpsum;
strata cstratm;
weight patwt;
title 'descriptive demographics';
options nofmterr;
run;
/*Clinical Descriptives: totproc totdiag*/
proc surveymeans data=nhamcs.nhamcs10ed_opdappend_end;
domain participant;
var totdiag totproc;
cluster cpsum;
strata cstratm;
weight patwt;
title 'totdiag totproc Descriptives';
options nofmterr;
run;
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/*Clinical Descriptives: chestpain triage hypotension bradycardia cardenz
cardmon ekg*/
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end;
tables participant*chestpain participant*triage participant*hypotension
participant*bradycardia participant*cardenz participant*cardmon
participant*ekg /row CL CLWT ;
cluster cpsum;
strata cstratm;
weight patwt;
title 'clinical descriptive';
options nofmterr;
run;
/*Visit Descriptives: arrival day time disch7da hdstat physcian resint
nursepr nurse physasst*/
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end;
tables participant*arrival participant*day participant*disch7da
participant*hdstat participant*physcian participant*resint
participant*nursepr participant*nurse participant*physasst/row CL CLWT;
cluster cpsum;
strata cstratm;
weight patwt;
title 'visit Descriptives';
options nofmterr;
run;
/*Hospital Descriptives: region metro ownership ereminde*/
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end;
tables participant*region participant*metro participant*ownership
participant*ereminde/row CL CLWT;
cluster cpsum;
strata cstratm;
weight patwt;
title 'hospital Descriptives';
options nofmterr;
run;
/*AIM 1: trend of aspirin_antiplatelet across years*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
model aspirin_antiplatelet (event ='1')= year;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'trend of aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 1: trend of betablocker across years*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
model betablocker (event ='1')= year;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'trend of betablocker';
options nofmterr;
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run;
/*Associations with Demographic Characteristics*/
/*AIM 2: age (older_65) and aspirin_antiplatelet (new_participant)*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class older_65 sex ptrace;
model aspirin_antiplatelet (event ='1')= older_65 sex ptrace;
domain new_participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'older_65 and new_participant and aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: age (older_65) and betablocker (new_participant)*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class older_65;
model betablocker (event ='1')= older_65;
domain new_participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'older_65 and new_participant and betablocker';
options nofmterr;
run;
/*AIM 2: sex and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class sex;
model aspirin_antiplatelet (event ='1')= sex;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'sex+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: sex and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class sex ptrace;
model betablocker (event ='1')= sex ptrace age;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'sex+ betablocker';
options nofmterr;
run;
/*AIM 2: race and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class ptrace;
model aspirin_antiplatelet (event ='1')= ptrace;
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domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'ptrace+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: race and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class ptrace;
model betablocker (event ='1')= ptrace;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'ptrace+ betablocker';
options nofmterr;
run;
/*AIM 2: ethnicity and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class ethnicity;
model aspirin_antiplatelet (event ='1')= ethnicity;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'ethnicity+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: ethnicity and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class ethnicity;
model betablocker (event ='1')= ethnicity;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'ethnicity+ betablocker';
options nofmterr;
run;
/*AIM 2: payment and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class payment;
model aspirin_antiplatelet (event ='1')= payment;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'sex+ aspirin_antiplatelet';
options nofmterr;
run;
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/*AIM 2: payment and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class payment;
model betablocker (event ='1')= payment;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'payment+ betablocker';
options nofmterr;
run;
/*AIM 2: residnce and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class ptresidnce sex ptrace;
model aspirin_antiplatelet (event ='1')= ptresidnce sex ptrace age;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'ptresidnce+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: residnce and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class ptresidnce;
model betablocker (event ='1')= ptresidnce;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'ptresidnce+ betablocker';
options nofmterr;
run;
/*Association with Clinical Characteristics*/
/*AIM 2: chestpain and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class chestpain;
model aspirin_antiplatelet (event ='1')= chestpain;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'chestpain+ aspirin_antiplatelet';
options nofmterr;
run;
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/*AIM 2: chestpain and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class chestpain ptrace sex;
model betablocker (event ='1')= chestpain age ptrace sex;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'chestpain+ betablocker';
options nofmterr;
run;
/*AIM 2: triage and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class triage sex ptrace;
model aspirin_antiplatelet (event ='1')= triage age sex ptrace;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'triage+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: triage and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class triage;
model betablocker (event ='1')= triage;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'triage+ betablocker';
options nofmterr;
run;
/*AIM 2: totproc and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
model aspirin_antiplatelet (event ='1')= totproc;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'totproc+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: totproc and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
model betablocker (event ='1')= totproc;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
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title 'totproc+ betablocker';
options nofmterr;
run;
/*AIM 2: totdiag and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class ptrace sex;
model aspirin_antiplatelet (event ='1')= totdiag sex age ptrace;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'totdiag+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: totdiag and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class sex ptrace;
model betablocker (event ='1')= totdiag sex ptrace age;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'totdiag+ betablocker';
options nofmterr;
run;
/*Association with Visit Characteristics*/
/*AIM 2: time and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_endingf;
class time;
model aspirin_antiplatelet (event ='1')= time;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'time+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: hours and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_endingf;
class time;
model betablocker (event ='1')= time;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'time+ betablocker';
options nofmterr;
run;
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/*AIM 2: day and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class day;
model aspirin_antiplatelet (event ='1')= day;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'day+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: day and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class day;
model betablocker (event ='1')= day;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'day+ betablocker';
options nofmterr;
run;
/*AIM 2: arrival and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class arrival sex ptrace;
model aspirin_antiplatelet (event ='1')= arrival sex ptrace age;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'arrival+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: arrival and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class arrival;
model betablocker (event ='1')= arrival;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'arrival+ betablocker';
options nofmterr;
run;
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/*AIM 2: physcian and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class physcian;
model aspirin_antiplatelet (event ='1')= physcian;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'physcian+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: physcian and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class physcian;
model betablocker (event ='1')= physcian;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'physcian+ betablocker';
options nofmterr;
run;
/*AIM 2: resint and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class resint;
model aspirin_antiplatelet (event ='1')= resint;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'resint+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: resint and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class resint;
model betablocker (event ='1')= resint;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'resint+ betablocker';
options nofmterr;
run;
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/*AIM 2: nurse and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class nurse;
model aspirin_antiplatelet (event ='1')= nurse;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'nurse+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: nurse and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class nurse;
model betablocker (event ='1')= nurse;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'nurse+ betablocker';
options nofmterr;
run;
/*AIM 2: nursepr and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class nursepr ptrace sex;
model aspirin_antiplatelet (event ='1')= nursepr ptrace sex age;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'nursepr+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: nursepr and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class nursepr;
model betablocker (event ='1')= nursepr;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'nursepr+ betablocker';
options nofmterr;
run;
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/*AIM 2: physasst and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class physasst;
model aspirin_antiplatelet (event ='1')= physasst;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'physasst+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: physasst and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class physasst;
model betablocker (event ='1')= physasst;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'physasst+ betablocker';
options nofmterr;
run;
/*Association with Hospital Characteristics*/
/*AIM 2: region and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class region;
model aspirin_antiplatelet (event ='1')= region;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'region+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: region and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class region;
model betablocker (event ='1')= region;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'region+ betablocker';
options nofmterr;
run;
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/*AIM 2: Metro and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class metro sex ptrace;
model aspirin_antiplatelet (event ='1')= metro sex ptrace age;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'metro+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: metro and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class metro;
model betablocker (event ='1')= metro;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'metro+ betablocker';
options nofmterr;
run;
/*AIM 2: ownership and aspirin_antiplatelet*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class ownership;
model aspirin_antiplatelet (event ='1')= ownership;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'ownership+ aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 2: ownership and betablocker*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class ownership;
model betablocker (event ='1')= ownership;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'ownership+ betablocker';
options nofmterr;
run;
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/*AIM 3: los and aspirin_antiplatelet (participant_los)*/
proc surveymeans data=nhamcs.nhamcs10ed_opdappend_end;
var los;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'descriptive los';
options nofmterr;
run;
proc surveyreg data=nhamcs.nhamcs10ed_opdappend_end;
model los = aspirin_antiplatelet / CLPARM;
domain participant_los;
cluster cpsum;
strata cstratm;
weight patwt;
title 'los+aspirin_antiplatelet';
options nofmterr;
run;
/*AIM 3: los and betablocker (participant_los)*/
proc surveyreg data=nhamcs.nhamcs10ed_opdappend_end;
model los = betablocker / CLPARM;
domain participant_los;
cluster cpsum;
strata cstratm;
weight patwt;
title 'los+betablocker';
options nofmterr;
run;
/*AIM 3: aspirin_antiplatelet and betablocker mortality*/
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end;
tables participant*aspirin_antiplatelet*hdstat participant*betablocker*hdstat
/ chisq row CL CLWT;
cluster cpsum;
strata cstratm;
weight patwt;
title 'hdstat*chisquare';
options nofmterr;
run;
/*AIM 4: descriptive ereminde*/
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_endingf;
tables participant*ereminde / row CL CLWT;
cluster cpsum;
strata cstratm;
weight patwt;
title 'descriptive ereminde';
options nofmterr;
run;
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/*AIM 4: antiplatelet and ereminde*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class ereminde;
model aspirin_antiplatelet (event ='1')= ereminde;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'antiplatelet+ereminde ';
options nofmterr;
run;
/*AIM 4: betablocker and ereminde*/
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end;
class ereminde;
model betablocker (event='1') = ereminde;
domain participant;
cluster cpsum;
strata cstratm;
weight patwt;
title 'ereminde+betablocker';
options nofmterr;
run;
/*Descriptive contraindication*/
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end;
tables participant*contraindication / row CL CLWT;
cluster cpsum;
strata cstratm;
weight patwt;
title 'descriptive contraindication';
options nofmterr;
run;
/*Descriptive betablockers*/
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end;
tables participant*betablocker / row CL CLWT;
cluster cpsum;
strata cstratm;
weight patwt;
title 'descriptive betablockers';
options nofmterr;
run;
/*chestpain and age*/
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end;
tables participant*agecat*chestpain / chisq row CL CLWT;
cluster cpsum;
strata cstratm;
weight patwt;
title 'descriptive chestpain';
options nofmterr;
run;
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/*sex and age*/
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end;
tables participant*agecat*sex / chisq row CL CLWT;
cluster cpsum;
strata cstratm;
weight patwt;
title 'descriptive sex*age';
options nofmterr;
run;
/*hdstat and age*/
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end;
tables participant*agecat*hdstat / chisq row CL CLWT;
cluster cpsum;
strata cstratm;
weight patwt;
title 'hdstat*age';
options nofmterr;
run;
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